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Glutaminase is the enzyme that converts glutamine into glutamate, which 
serves as a key excitatory neurotransmitter and one of the energy providers for 
cellular metabolism. Glutamate is essential for proper brain functioning but at 
excess levels, it is neurotoxic and has a key role in the pathogenesis of various 
neurodegenerative diseases, including HIV-1 associated neurocognitive 
disorders (HAND). However, the detailed mechanism of glutamate-mediated 
neurotoxicity remains unclear. In part I, we identified the regulation of 
glutaminase 1 (GLS1) in the central nervous system (CNS) of HAND animal 
models including HIV-Tat transgenic (Tg) mouse and HIVE-SCID mouse, since 
GLS1 is the dominant isoform of glutaminase in mammalian brains. Interestingly, 
examinations of both animals revealed an upregulation of GLS1 in correlation 
with the increase of brain inflammation and cognitive impairment. As our previous 
data revealed an upregulation of glutaminase C (GAC) in the postmortem brain 
tissues of patients with HIV dementia by protein analysis, suggesting a critical 
role of GAC in the instigation of primary dysfunction and subsequent neuronal 
damage in HAND, thus in part II we hypothesize that GAC dysregulation in brain 
is sufficient to induce brain inflammation and dementia in relevance to HAND. 
Using a brain GAC overexpression mouse model (which has the overexpression 
of GAC confined in the brain), we found that the expressions of the marker for 
brain inflammation, the glial fibrillary acidic protein (GFAP), were increased in the 
brains of GAC-overexpression mice, suggesting increased reactive astrogliosis. 
To study the functional impact of GAC overexpression, we performed Morris 
Water Maze (MWM) test and Contextual Fear Conditioning (CFC) test to 
determine the learning and memory of mice. GAC-overexpression mice 
perfomed poorer in both tests, indicating that overexpressing GAC in mouse 
brain impaired the learning and memory of the animals. Moreover, pathological 
and physiologial examinations revealed synaptic damage and increased 
apoptosis in Nestin-GAC mouse brain. Together, these data suggest that 
dysregulated GAC has a causal relationship with prolonged inflammation and 
dementia relevant to HAND. In part III, we evaluated the feasibility of genetically 
knocking down GLS1 in CNS to treat HAND using human primary neural 
progenitor cell (NPC) culture. However, we have found that GLS1 is essential for 
the survival, proliferation and differentiation of human NPC. This suggests that 
more-advanced genetic methods capable of targeting GLS1 in specific cell types 
of CNS ought to be developed for the therapeutic purpose.  
In summary, we report that GLS1 is dysregulated in the brains of HAND 
murine models in correlation with increased brain inflammation and cognitive 
impairment. Moreover, overexpressed GAC in mouse brains has a causal 
relationship to prolonged brain inflammation and dementia of these animals, 
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1.1 HIV-1 associated neurocognitive disorders 
1.1.1 Clinical manifestations 
       HIV infection continues to cause substantial morbidities worldwide. Till 
2013, 35 million people are living with HIV around the world. HIV-1 infection 
accounts for more than 90% of the global HIV pandemic, with the fact that fewer 
than 3 million of the 35 million infections are caused by HIV-2 [1]. 
        HIV-1 associated neurocognitive disorders (HAND) represent a spectrum 
of cognitive disorders caused by HIV infection. These disorders are 
characterized by cognitive deteriorations, behavioral disorders and potential 
progressive motor impairments as a consequence of neuronal damage [2]. 
These disorders affect up to 50% of HIV-1 infected individuals [3]. HAND 
comprise three categories based on standardized measures of dysfunction: HIV-
1 associated dementia (HAD), mild neurocognitive disorder (MND), and 
asymptomatic neurocognitive impairment (ANI) [4]. With the effective treatment 
by highly active antiretroviral therapy (HAART), the occurrence of HAD, the 
most severe and devastating form of HAND, has dramatically fallen [5]. 
However, even the incidence of moderate or severe form of HAND, MND and 
HAD, has largely declined since the introdction of HAART in 1996,  the 
prevalence of HAND remains high (15-50%) [5, 6] with the increase of the life 
span of HIV-infected individuals [7], emergence of drug-resistant viral mutants 
[8, 9], compromised blood-brain barrier (BBB) penetration of HAART [10], and 
sustained HIV infection and virus production in mononuclear phagocytes 
(macrophages and microglia) of the brain [5, 11]. The high prevalence of the 
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milder forms of HAND is still significant because cognitive impairment continues 
to be a commonplace and interferes with everday functioning like employment, 
finance management, driving, housekeeping and adherence to medications of 
HIV-infected individuals.  
 
1.1.2 Pathobiology of HAND 
The most severe form of HAND, HAD, is a synonym of HIV 
encephalopathy or AIDS dementia complex [5]. Its pathological correlate is 
termed HIV-1 encephalitis (HIVE). The pathological characteristics of HIVE 
include progressive infection within perivascular monocyte-derived 
macrophages (MDM), the infiltration of MDM into the brain, and often the 
formation of multinucleated giant cells due to the fusion of HIV-infected MDM 
[12, 13]. Other pathological features include reactive astrogliosis, diffuse 
rarefaction of white matter, BBB breakdown, simplification and decrease of 
synaptic dendrites, and neuronal loss [14-16].  
Cognitive impairment in HAND is a consequence of synaptic network 
damage in basal ganglia, cerebral cortex and hippocampus of HAND patients. 
Morphometric studies have revealed approximately 40% decreases in the 
densities of neurons in the frontotemporal cortex [14, 17], and 50% - 90% 
decreases of neuronal densities in hippocampus [18] before the HAART era. 
Previous studies with in situ hybridization have confirmed that productive HIV-1 
infections occur almost exclusively in perivascular MDM [19]. Brain microglia are 
infected by HIV-1 to a lesser degree while astrocytes are only non-productively 
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or restrictively infected due to the fact that CD4 is not present on them [20-25]. 
Neurons are not infected by HIV-1 [20]. Since neurons have the lowest 
susceptibility to HIV infection among all cells in the central nervous system 
(CNS), their dysfucntion largely results from HIV infection of nerboring cells. 
Initially, HIV-infected perivascular macrophages enter into CNS via the broken 
BBB, bringing HIV that has the ability to infect brain macrophages and microglia. 
Infection of macrophages and microglia results in production of viral proteins 
and neurotoxins [26-29] that start to damage synapses, thus disrupt the 
connections of neuronal network and neurotransmission at first stage. HIV-
infected macrophages and microglia can serve as long-lived reservior for the 
virus production in the brain, leading to progressive neuronal damage [14, 30]. 
And importantly, those viral proteins released by infected macrophages and 
microglia activate uninfected macrophages, microglial and astrocytes, resulting 
in the production of more viral proteins, a variety of proinflammatory molecules 
and neurotoxins [28, 29, 31, 32], leading to prolonged brain inflammation and 
further damage to neurons at the second stage [33-37]. Studies have shown 
that the severity of HAND is significantly associated with the densities of 
activated brain macrophages, microglia, and astrocytes, and with the expression 
levels of the neurotoxins secreted by those activated brain cells [38]. 
 
1.2 Excitotoxicity 
 Chronic neuroinflammation is a hallmark of HAND and a constitutive 
component of the pathogenesis of neurodegenerative diseases including HAND, 
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multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease and 
Alzheimer’s disease [33-35]. Literature have suggested a close link between 
brain inflammation and neuronal injury [36, 39]. HIV-infected and activated 
microglia and macrophages instigate brain inflammation and induce neuronal 
injury through the production and release of various soluble neurotoxic factors 
including viral proteins [30], platelet activating factor [40-43], proinflammatory 
cytokines and chemokines [37, 44-47], nitric oxide [48, 49], and excess 
glutamate [32, 50-52]. Apart from brain macrophages, microglia and astrocytes, 
neurons play a critical role in the progress of brain inflammation as well. 
Specifically, proinflammatory cytokines TNF-α and IL-1β, which are typically 
elevated during neurodegenerative diseases, induced neuronal loss via the 
production and release of excess glutamate in neuronal culture [53].   
Glutamate is the most important excitatory neurotransmitter in 
mammalian CNS [54, 55]. It is essential for vital physiologic processes including 
neural development, synaptic plasticity, learning and memory [55-57]. However 
at excess levels, glutamate has the potential to induce extensive neuronal injury, 
which is termed excitotoxicity. Excess glutamate causes neuronal damage via 
overactivation of glutamate receptors. Studies of the neurotoxic effects of viral 
proteins like HIV-1 coat protein glycoprotein 120 (Gp120) and HIV trans-acting 
protein Tat have revealed that viral proteins induced modification of the kinectics 
of NMDA receptors located on postsynaptic neruons via stimulating the release 
of arachidonic acid from infected glial cells [58]. The combination of the 
increased pool of extracellular glutamate and overactivated NMDA receptors 
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results in calcium overload within neurons [59]. Calcium is one the most 
important second messagers in neural signal transduction. Deregulated calcium 
leads to oxidative stress including production of free radicals and disruption of 
redox balance, and results in mitochondrial dysfunction, caspase activation and 
cellular death [60]. Besides, lipid imbalance in neurons has also been 
associated with calcium overload-induced neuronal dysfunction or death in 
HAND [59, 61]. The moderate-affinity glutamate receptor antagonist memantine 
has been reported to have successfully reversed HIV viral protein-induced 
calcium overload in neurons and substantially protected neurons from apoptosis 
[62-64].  
Therefore, elevated glutamate has been linked to the pathogenic 
processes of various CNS disorders [65-68] and neurodegenerative diseases  
including HAND [50, 69, 70].  
 
1.3 Glutaminase 1  
In mammalian CNS, glutamate is typically derived from glutamine by the 
action of an phosphate-activated amidohydrolase named glutaminase (EC 
3.5.1.2) [71]. Two different kinds of glutaminase are found in mammals. The 
predominant glutamine-utilizing and glutamate-producing enzyme in CNS is 
glutaminase 1 (GLS1), a mitochondrial hetero-tetramer localized on the inner 
membrane of mitochondria, whereas the isozyme glutaminase 2 (GLS2) is 
expressed at lower levels [72] in the brain.  
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GLS1 and GLS2 are encoded by separate genes on different 
chromosomes [73]. The human Gls1 gene is on chromosome 2 [74] and has 
several isoforms due to tissue-specific alternative splicing. Two splice variants of 
GLS1, glutaminase C (GAC) and kidney-type glutaminase (KGA), are found in 
mammalian brain tissues [75]. GAC shares the same functional region of KGA 
and possesses a unique C-terminal [76]. Glutaminase catalyzes the following 
reaction: Glutamine + H2O → Glutamate + NH3. Glutamate is subsequently 
converted to α-ketoglutarate with the catalysis by glutamate dehydrogenase. 
The end-product α-ketoglutarate enters into the tricarboxylic acid (TCA) cycle 
that maintains the energy generation. Therefore, GLS1 plays an essential role in 
generating neurotransmitter and brain bioenergetics.  
In the brain under physiological conditions, GLS1 is expressing at highest 
levels in neurons and to relatively lesser extents in astrocytes, microglia and 
macrophages. The expression profile of GLS1 in different cells of the brain is in 
agreement with the compartmentation of the glutamate-glutamine cycle that is 
critial for neural signal transmission in CNS. 
 
1.4 Glutamate - glutamine cycle in the brain 
There is not a clearly-defined starting point of the glutamate-glutamine 
cycle. We begin with events that occurred in the presynaptic neurons. In 
presynaptic neurons, glutamine is converted to glutamate by GLS1 and the 
newly-produced glutamate is packaged into presynaptic vesicles. The 
glutamate-filled vesicles are recruited and docked to specialized release sites 
  8 
that are dense electron regions termed the active zones of presynaptic neurons 
[77]. Intracellular calcium influxes trigger the release of glutamate-containing 
vesicles from presynaptic nerve terminals into synaptic cleft via exocytosis [77, 
78]. Afterwards, glutamate diffuses across the synaptic cleft and binds to 
glutamate receptors located on postsynaptic neurons. The binding of glutamate 
with its receptors alters membrane potential of the postsynaptic neurons and 
triggers downstream signal transduction cascades. There are two major types of 
glutamate receptors: the ionotropic glutamate receptors that are ligand-gated ion 
channels including AMPA, NMDA, kainate and Delta receptors [79]; and the 
metabotropic glutamate receptors that are G protein-coupled receptors including 
metaotropic glutamate receptor 1-8 [80].  
Glutamate that resides in the synaptic cleft is utilized or removed rapidly 
via three major ways. First, glutamate is uptaken by postsynaptic neurons for 
neural signal transmission. Second, some glutamate is reuptaken by 
presynaptic neurons via glutamate transporters located on neurons. Third, a 
substantial amount of extra glutamate in synaptic cleft is transported to 
neighboring astrocytes by glutamate transporters located on astrocytes. As the 
resting membrane potential of astrocytes is relatively low compared to that of 
neurons, extracellular glutamate is favorably efficiently uptaken by astrocytes 
through a sodium-dependent mechanism [81]. Within astrocytes, where the 
enzyme glutamine synthase is expressing at high levels, the majority of 
glutamate is converted back to glutamine [82]. The newly-synthesized glutamine 
is released extracellularly and transported back to neurons by glutamine 
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transporters [83]. Then in neurons, glutamine is converted to glutamate. With 
the regeneration of glutamate in neurons, the glutamate-glutamine cycle has 
“closed”.  
Importantly, the reaction of deaminating glutamine to produce glutamate 
by GLS1 is energetically favorable. So GLS1 must be tightly regulated to 
prevent excess glutamate generation and excitotoxicity [73]. 
 
1.5 The possible pathological role of GLS1 in HAND 
Although the exact way in which HIV causes HAND remains incompletely 
understood, GLS1 has been reported to have a crucial role in mediating 
excitotoxicity. In the past decade our laboratory and others have helped with 
defining the excitotoxic profile of brain macrophages and microglia. We have 
developed molecular and chemical tools with explicit intent to understand HAND 
pathogenesis and to find an effective treatment for HAND. Along with others, we 
identified that human macrophages and microglia infected by HIV-1 were 
substantially involved in the generation of excess extracellular glutamate [50, 
84]. This generation of excess glutamate represents a major component of 
macrophage –, or microglia – mediated neurotoxicity [85]. Notably, we have 
demonstrated that the neuroinflammatory and neurotoxic events of 
macrophages and microglia infected by HIV-1 are augmented by GLS1 in vitro 
[71, 84, 86]. And importantly, we have determined that GLS1 dysregulation is a 
key event in neuroinflammation required for excess glutamate generation in 
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HIV-1 infection – induced neurotoxicity [87, 88]. And interestingly, GLS1 release 
is involved in extracellular glutamate production [85, 89, 90]. 
So together we have documented roles of GLS1 in microglia and 
macrophages in brain injury, infection and inflammation [50, 86, 90] and more 
recently the regulation and function of GLS1 in neurons under inflammation [53].  
 
1.5.1 Pathogenic role of macrophage GLS1 in HAND 
HIV-1-infected macrophages have been reported to be a critial cellular 
source of extracellular glutamate. In the past decade, we have reported an HIV-
1-mediated increase of glutamate generation by MDM [50]. The examination of 
GLS1 regulation in HIV-1-infected MDM has revealed an isoform-specific 
upregulation of GAC expression, while the expression of KGA remains largely 
unchanged. The siRNA targeting GAC in HIV-1-infected MDM has substantially 
decreased the production of glutamate [90]. In addition, rat cortical neurons 
treated by macrophage-conditioned medium (MCM) from HIV-1-infected MDM 
have shown significant toxicity, which, can be largely reversed by removing 
glutamine from the MCM, antagonizing NMDA receptor, inhibiting GLS1 activity 
with pharmacological inhibitors, or targeting GAC with siRNA [85]. Together, 
these studies demonstrate a pathogenic role of macrophage GAC in mediating 
excitotoxicity and disease progressions of HAND [90].  
 
1.5.2 Pathogenic role of microglial GLS1 in HAND  
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Microglia are the main cellular targets of HIV-1 infection in CNS. The HIV-
1-infected- or immune-activated microglia have been reported to play an 
important pathogenic role in HAND. Specifically, our laboratory has 
demonstrated that HIV-1-infected microglia have substantially-increased 
glutamate production and are largely more neurotoxic than uninfected microglia 
using a human microglia primary culture system. Consistent with the findings in 
HIV-1-infected MDM, the examinations of GLS1 RNA and protein levels in HIV-
1-infected microglia have revealed an isoform-specific upregulation of GAC. And 
importantly, targeting GAC by siRNA and inhibiting GLS1 using pharmacological 
inhibitors have successfully reversed the excess glutamate production and the 
neurotoxic effects of HIV-1-infected microglia [84]. Again, these findings support 
that glutaminase as an important component of the pathogenic process of 
HAND.  
 
1.5.3 Pathogenic role of neuronal GLS1 in HAND 
Despite the fact that neurons having the highest expression levels of 
GLS1 in CNS, little is known about the role of neuronal GLS1 in mediating 
excitotoxcity of HAND until recently. In 2013, our laboratory has reported that 
both human and rat primary neurons treated by two proinflammatory cytokines 
that are typically elevated in neurodegenerative conditions, interleukin-1β (IL-1β) 
and tumor necrosis factor-α (TNF-α), produce substantially-increased 
intracellular and extracellular glutamate. The increase in glutamate production 
by those neurons under inflammation has induced toxic effects as the viability of 
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other neurons treated by the conditioned medium from inflammtory cytokines-
treated neurons is largely decreased. GLS1 isoform KGA has been found to be 
significantly upregulated in both human and rat primary neurons under 
inflammation. And importantly, the neurotoxic effects are reversed by inhibiting 
GLS1 activity with pharmacological inhibitors or by antagolizing NMDA receptors 
[53]. Taken together, these results demonstrate a critical role of dysregulated 
GLS1 in neurons in mediating the progresses of brain inflammation and 
excitotoxicity in HAND.  
 
1.6 Conclusion 
Excitotoxicity mediated by excess glutamate production and 
overactivation of NMDA receptor is a basic componenet of various 
neurodegenerative disorders [50, 69, 70]. Specifically in HAND, excess 
glutamate generation seems to be a critical contributor although a number of 
factors clearly affect the pathogenesis of HAND. Glutamine, the substrate for the 
production of glutamate by GLS1 in the brain, is abundantly available at the 
millimolar range. In CNS, GLS1 catalyzes the deamination of glutamine to 
produce glutamate in an energetically favorable process. It is important to 
identify the specific cell type accounting for excess glutamate generation and 
understand the underlying mechanisms. With explicit effort, our laboratory with 
others have demonstrated that increased glutamate generation and release, 
decreased glutamate reuptake by presynaptic neurons, and reduced glutamate 
uptake by astrocytes all contribute to excess extracellular level of glutamate [91-
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93]. We have documented the ciritcal roles of GLS1 dysregulation in brain 
macrophages, microglia, and inflammatory neurons, in excess glutamate 
production and augmentation of brain inflammation and neurotoxicity in vitro [50, 
86, 90] [53].  
To verify the clinical relevance of these findings, we investigated the 
expression levels of GLS1 in the postmortem brain tissues of HIV-1-infected 
patients with dementia. Importantly, we have identified an isoform-specific 
upregulation of GAC levels in the postmortem brain tissue of HAND patients 
comparing with that of HIV serum-negative controls, and the increased levels of 
GAC are correlated with elevated concentrations of glutamate in HAND patients’ 
postmortem brain tissues [84, 90].  
These results suggest that in a disease involving progressive 
neuroinflammation and excitoxicity as HAND, the aberrantly upregulated or 
released GLS1 plays a pathogenic role. Even more importantly, the findings that 
by targeting the dysregulated GLS1 with pharmacological inhibitors or siRNA 
reversed neuroinflammation or neurotoxicity strongly indicate that GLS1 can be 
a potentially valuable therapeutic target for treating HAND. 
In order to further determine the pathogenic role of aberrantly regulated 
GLS1 and further investigate GLS1 as a new therapeutic target for HAND, we 
have started to utilize integral animal models to study the role of aberrantly 
regulated GLS1 in HAND pathogenesis and the underlying mechanisms in vivo. 
We hypothesize that there is strong association between GLS1 dysregulation 
and brain inflammation or cognitive impairment of HAND animals, and the brain-
  14 
specific overexpression of GLS1 will have a causal effect on inducing 
neurotoxicity. 
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1.7 Figures 
Figure 1.1 Proposed model for the pathogenic role of dysregulated 
GLS1 in HAND. Previous studies revealed that GLS1 levels are increased in 
the HIV-1-infected macrophages and microglia. Viral proteins and neurotoxins 
secreted by infected brain macrophages and microglia activate uninfected 
microglia, macrophages, and astrocytes. Activated microglia, macrophages, and 
astrocytes release more neurotoxins and inflammatory molecules that damage 
neurons via overactivation of NMDA receptors. Neurons treated by 
proinflammatory cytokines have increased levels of GLS1. Inflammatory 
neurons secrete excess glutamate extracellularly and cause further damage to 
neurons. 
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2.1 Abstract 
Glutaminase is the enzyme that converts glutamine into glutamate, which 
serves as a key excitatory neurotransmitter and one of the energy providers for 
cellular metabolism. Glutamate is essential for proper brain functioning but at 
excess levels, it is neurotoxic and has a key role in the pathogenesis of various 
neurodegenerative diseases, including HIV-1 associated neurocognitive 
disorders (HAND). However, the detailed mechanism of glutamate-mediated 
neurotoxicity remains incompletely understood. Our previous data revealed that 
GLS1 dysregulation is a key event in neuroinflammation and excess glutamate 
production in HIV-1-infected macrophages and microglia, and in neurons treated 
by inflammatory cytokines in vitro. But the regulation of GLS1 and its association 
with the progressions of neuroinflammation and neurotoxicity in vivo remains 
unknown. Using the well-established HAND murine models, the HIV trans-
activator of transcription (HIV-Tat) transgenic (Tg) mouse and HIVE-severe 
combined immunodeficient (SCID) mouse, we identified that GLS1 isoforms 
were upregulated in whole brain tissues of HIV-Tat Tg mouse and in the 
neuroinflammatory areas of HIVE-SCID mouse brains. The elevated GLS1 
expression levels were correlated with increased CNS astrogliosis and impaired 
spatial learning and memory of HIV-Tat Tg mouse, suggesting that GLS1 
dysregulation is strongly associated with the pathogenesis of HAND. Together, 
these data imply a pathogenic role of GLS1 dysregulation for HAND in vivo. 
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2.2 Introduction 
Non-human primates infected by the simian immunodeficiency virus (SIV) 
or by chimeric SIV/HIV viruses best mimic human HIV disease among all animal 
models. However, murine models possess notable advantages in consideration 
of advanced and easy-to-handle genetic methods for mouse genome 
manipulation, comparably low cost of maintaining animals and less difficulty of 
handling animals.  
Given the fact that HIV is not infectious to murine species, generating 
small animal models to mimic the human pathology of HAND is a very 
challeging job. To date, the well-established and accepted murine models for 
HAND include: HIV-1 glycoprotien 120 (gp120) Tg mouse, HIV-Tat Tg mouse, 
the humanized mouse, and HIVE-SCID mouse [94]. HIV-Tat Tg mouse and 
HIVE-SCID mouse represnet two major different approaches of making murine 
models for HAND.  
Generating Tg mouse models was among the very first endeavors for the 
study of HAND pathology in vivo. But it was not until recently that HIV-Tat Tg 
mouse has been well-accepted and extensively used as a HAND murine model. 
Tat is the first protein produced by HIV-1-infected cells. Upon secreted, Tat can 
invade and enter into most cell types of the human body via its arginie-rich 
domain. Importantly, Tat production is not significantly affected by the combined 
antiretroviral therapy (cART) as recent studies demonstrate that Tat is present in 
the cerebrospinal fluid (CSF) of HIV-1-infected individuals virologically controlled 
under cART [95]. This makes HIV-Tat Tg mouse the most popular HAND Tg 
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murine model in the post-HAART era [96, 97] because although gp120 is the 
most prominent viral antigen found in the lysates of HIV-1-infected cells [98] and 
gp120 can be shed by infected macrophages and activated astrocytes in CNS to 
cause neuronal damage, its production is largely reduced by sustained cART. 
Several HIV-Tat Tg mouse models have been created to understand the 
contribution of Tat protein to HAND progressions [96, 99-101], among which, the 
brain-specific HIV Tat Tg mouse under the control of the GFAP promoter with 
doxycycline-inducible system (GFAP-Tat) is one of the best characterized and 
most widely used [96, 101]. In this study, we utilized the GFAP-Tat Tg mouse. 
This line of mouse will be referred to as HIV-Tat Tg mouse in the rest of text. 
Besides Tg mouse, another major approach for generating HAND murine 
models is by transplanting human cells or tissues into genetically modified 
immunodeficient mice. The HIVE-SCID mouse is created by implanting HIV-1-
infected macrophages directly into the basil ganglia of SCID mice [102]. These 
mice persistently express HIV p24 antigen in the brain and can survive up to 5 
weeks following cell implantation [103].  
Neuroinflammation, excitotoxicity, synaptic damage and cognitive 
impairments have been found in both HIV-Tat Tg mouse and HIVE-SCID 
mouse. However, the regulation of GLS1 in CNS of these animals and the 
asssociation of GLS1 regulation with brain inflammation and neuronal damage 
remains unknown. In this chapter, we report that the GLS1 isoforms were 
upregulated in whole brain tissues of HIV-Tat Tg mouse and in the 
neuroinflammatory areas of HIVE-SCID mouse brains. The elevated GLS1 
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expression levels were correlated with increased CNS astrogliosis and impaired 
spatial learning and memory of HIV-Tat Tg mouse. 
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2.3 Materials and methods 
Animals 
C.B.-17-SCID mice of four weeks of age were purchased from Jackson 
Laboratory (Bar Harbor, ME). The GFAP-Tat Tg mice were generously provided 
to us by Dr. Kurt Hauser from Virginia Commonwealth University. The GFAP-Tat 
Tg mouse model was originally developed by Dr. Avindra Nath. Distribution of 
this model was allowed by Dr. Nath. All animals were housed and bred in the 
Comparative Medicine facilities of the University of Nebraska Medical Center. All 
procedures were conducted according to protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Nebraska Medical 
Center. All Tg mice were genotyped through PCR reactions. DNA of embryonic 
tissue or adult mouse-tail tissue was extracted with phenol/chloroform, and 
purified by isopropanol and ethanol for PCR reactions. The primers used for 
genotyping are listed in Table 2.1. 
MDM isolation, culture, HIV-1 infection and implantation to SCID mice 
Human monocytes recovered from peripheral blood mononuclear cells of 
healthy donors (HIV-1, 2 and hepatitis B seronegative donors) after 
leukopheresis and counter current centrifugal elutration [104] were cultured as 
adherent monolayers at the density of 1.1 x 106 cells / well in the 24-well plates 
for 7 days. The medium for cultivating monocytes is Dulbecco’s modified Eagles 
medium (DMEM, GIBCO Invitrogen Corp, Carlsbad, CA) with 10% heat-
inactivated pooled human serum (Cambrex Bio Science, Walkersville, MD), 50 
µg/ml gentamicin, 10 µg/ml ciprofloxacin (Sigma-Aldrich, St. Louis, IL) and 1000 
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U/ml highly purified recombinant human macrophage colony stimulating factor 
(M-CSF) (Generously provided to us by Wyeth Institute, Cambridge, MA).  
One week after being plated, MDM were infected by the laboratory HIV-
1ADA strain at a multiplicity of infection (MOI) of 0.1 virus per cell. On day after 
infection, HIV-1ADA-infected MDM (5 x 105 cells in 5 µl per mouse) were 
intracranially injected into the basil ganglia of SCID mice by stereotactic 
methods [103]. Duplicate SCID mice receiving intracranial injections of 
uninfected MDM (5 x 105 cells in 5 µl per mouse) served as controls.  
Morris-Water-Maze (MWM) Test 
One week after the intracranial injection of MDM, HIVE-SCID mice were 
subjected to MWM test for behavior characterization. MWM test consists two 
parts, the training phase and probe test. Mice were introduced into a circular, 
water-filled tank, 91 cm in diameter and 110 cm in height. The tank was equally 
divided into four quadrants. Visual cues were placed around the pool in plain 
sight of the mouse to flag the submerged platform (10 cm in diameter). Various 
parameters of mouse movement were recorded, including the time spent in 
each quadrant of the pool, the time taken to reach the platform (escape latency), 
and the total distance traveled.  For each trial, the mouse was allowed no more 
than 60 seconds to find the submerged platform before they were guided to the 
platform, removed from water, towel dried and returned to their cage. Each 
mouse will complete 4 trials per day during the 5-day training phase. 
Immediately after the training, the probe test was conducted. For the probe test, 
the platform was removed and each mouse was still given 60 seconds to swim 
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in the water. The swimming was videotaped analyzed by Ethovision XT (Noldus, 
Netherlands). The same test was done in HIV-Tat mice. 
Brain-tissue protein extraction and Western-blot 
After behavior tests, a set of animals were sacrificed and the whole 
brains were removed. The dissected tissues were homogenized by M-PER 
Protein Extraction Buffer (Pierce, Rockford, IL) containing 1× protease inhibitor 
cocktail (Roche Diagnostics, Indianapolis, IN). Protein concentrations were 
determined using a BCA Protein Assay Kit (Pierce). Proteins (5-10 µg) from 
tissue lysates were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). After electrophoretic transfer to 
polyvinyldifluoridene (PVDF) membranes (Millipore and Bio-Rad), proteins were 
treated with purified primary antibodies for KGA (rabbit, Dr. N. Curthoys, 
Colorado State University, 1:1000), GAC (rabbit, Dr. N. Curthoys, Colorado 
State University, 1:500), GFAP (mouse, cat#3670S, cell signaling, 1:1000), or β-
actin (mouse, Sigma-Aldrich, 1:10,000) overnight at 4 oC followed by a 
horseradish peroxidase-linked secondary anti-rabbit or anti-mouse antibody 
(Cell Signaling Technologies, 1:10,000).  Antigen-antibody complexes were 
visualized by Pierce ECL Western Blotting Substrate (Pierce). For data 
quantification, films were scanned with a CanonScan 9950F scanner; the 
acquired images were then analyzed on a Macintosh computer using the public 
domain NIH Image J program (at http://rsb.info.nih.gov/nih-image/). 
Analyses of glutamate concentrations 
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The intracellular glutamate levels in whole brain lysates of mice were 
determined by Amplex Red Glutamic acid / Gutamate oxidase Assay Kit 
(invitrogen) based on the manufacturer’s instruction. Brain tissue lysates were 
diluted to the same protein concentration before entering the assay.        
Statistical analyses 
Data were analyzed as means ± SEM. The data were evaluated 
statistically by the analysis of variance (ANOVA) followed by Tukey-test for 
pairwise comparisons by using GraphPad Prism software. The two-tailed 
Student’s t test was used to compare means of two groups. Correlations were 
determined by Spearman correlation. Significance was considered when P < 
0.05. All experiments were performed with at least three mice in each group to 
account for any individual animal-specific differences. Assays were performed at 
least three times in triplicate or quadruplicate. 
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2.4 Results 
GLS1 isoforms are upregulated in HIV-Tat Tg mice brains 
Our previous data revealed an upregulation of GLS1 in the 
neuroinflammatory areas of HIVE-SCID mouse brain [53]. To validate and 
further study the upregulation of GLS1 isoforms in CNS of HAND murine 
models, we examined the expression levels of GLS1 isoforms KGA and GAC in 
the whole brain tissue lysates of HIV-Tat Tg mice. In agreement of the 
upregulation of GLS1 in HIVE-SCID mouse brains, protein analyses by 
Western-blot revealed that the protein levels of both KGA and GAC were 
elevated in HIV-Tat Tg mice brains compared to that in wide-type (WT) 
littermate controls (Figure 2.1A-B). In parallel with the upregulation of GLS1 
isoforms KGA and GAC, analysis of glutamate levels in the whole brain tissue 
lysates revealed a significant increase of glutamate production in HIV-Tat Tg 
mice brains (Figure 2.1C). Together, these data demonstrate that GLS1 
isoforms were aberrantly upregulated in CNS of HIV-Tat mice and the 
upregulated GLS1 produced more glutamate. 
HIV-Tat Tg mice have increased astrogliosis in correlation with the 
elevated GLS1 isoform expression levels and brain glutamate levels 
Protein analysis by Western-blot confirmed a significant increase of 
GFAP expression levels in HIV-Tat Tg mice brain tissue lysates, demonstrating 
for an increased ongoing astrogliosis in these animals (Figure 2.2A-B). 
Importantly, the elevations of KGA protein levels and glutamate levels in the 
whole brain tissue lysates of HIV-Tat Tg mice were significantly correlated with 
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the increase of the expression levels of GFAP (Figure 2.2C,E), and the 
elevations of GAC protein levels is marginally correlated (P = 0.09) with the 
increase of the expression levels of GFAP (Figure 2.2D). Together, these data 
suggest a significant association between GLS1 dysregulation and increased 
brain inflammation. 
HIV-Tat Tg mice and HIVE-SCID mice displayed impairments in spatial 
learning and memory 
Previous studies have reported behavior deficits in learning and memory 
of HAND patients and animals. To behaviorally characterize and validate the 
cognitive deficits of HIV-Tat Tg mouse and HIVE-SCID mouse, we carried out 
the  MWM test to determine the spatial learning and memory of these animals.  
During the training phase of MWM test, HIV-Tat Tg mice displayed longer 
escape latency (time spent to reach the submerged platform) (Figure 2.3A) and 
travelled longer distance to escape (Figure 2.3B), indicating that HIV-Tat mice 
had impaired capabilities in learning to escape from water. Meanwhile, HIV-Tat 
Tg mice had similar swimming velocities comparing with that of WT control 
littermates (Figure 2.3C). This demonstrates that the impairment of learning in 
HIV-Tat Tg mice is not due to deficits in motor functions. Likewise, HIV-Tat Tg 
mice spent significantly less time in the target quadrant (Q2, where the escape 
platform was during the training phase) in the probe test than that spent by WT 
control littermates (Figure 2.3D). These results indicate that Nestin-GAC mice 
are impaired in spatial learning and memory.  
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Importantly, HIVE-SCID mice also exhibited longer escape latency during 
the training phase (Figure 2.4A) and had significantly less time spent in the 
target quadrant Q2 in the probe test (Figure 2.4B) comparing to SCID mice 
injected with infected MDM. Together, these results demonstrate that HIV-Tat 
Tg mice and HIVE-SCID have deficits in learning and memory related to 
hippocampal and cortical functions.  
Elevations of the expression levels of GLS1 isoforms and brain glutamate 
levels are in correlation with the behavior impairments in spatial learning and 
memory of HIV-Tat Tg mice 
Correlation analyses were made to determine the associations between 
GLS1 dysregulation and behavior deficits in spatial learning and memory of HIV-
Tat Tg mice. Correlation analyses revealed that GAC protein levels and brain 
glutamate levels were positively correlated with the escape latencies on the last 
day of MWM training phase (Figure 2.5B-C), and KGA protein levels were 
marginally positively correlated with the escape latencies (Figure 2.5A). Also, 
the elevation of brain glutamate levels was negatively correlated with the times 
that animals spent in the target quadrant Q2 of MWM probe test (Figure 2.5D). 
Therefore, these data indicate a strong association between GLS1 dysregulation 
and the spatial learning and memory impairments of HIV-Tat Tg mice. 
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2.5 Discussion 
 Understanding the regulation GLS1 and its association with brain 
inflammation, neurotoxicity, and cognitive impairments in HAND animal models 
will give the first clue towards the identifcation of whether GLS1 dysregulation 
has a pathogenic role and whether GLS1 can be a potential therapeutic target 
for HAND. In this chapter, we studied the regulation of GLS1 isoforms and the 
production of glutamate by GLS1 in HAND murine models. We report that the 
GLS1 isoforms were upregulated in the whole brain tissues of HIV-Tat Tg 
mouse and in the neuroinflammatory areas of HIVE-SCID mouse brains. The 
elevated GLS1 expression levels were correlated with increased CNS 
astrogliosis and impaired spatial learning and memory of HIV-Tat Tg mouse. 
These data support our central hypothesis that GLS1 dysregulation contributes 
to HAND pathogenesis via mediating brain inflammation and excitotoxicity. 
Aberrant GLS1 upregulation and excess glutamate production in HIV-1-
infected macrophages [73, 85, 86, 90], microglia [84-86] and in neurons under 
inflammation [53] has been well-characterized in vitro, and increased glutamate 
and upregulated GLS1 levels were found in HAND patients [84, 105]. The 
current study is the first to report an aberrant upregulation of GLS1 isoforms in 
the well-accepted and widely used HAND murine model, HIV-Tat Tg mouse; 
and the first to link GLS1 dysreuglation with neuroinflammation and cognitive 
impairments of HAND animals in vivo.  
At current stage, we have determined the aberrant upregulation of GLS1 
isoforms KGA and GAC in the whole brain tissues of HIV-Tat Tg mice. It will be 
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interesting and important to document the expression profiles of KGA and GAC 
in different areas of HIV-Tat Tg mice brains. Unlike HIVE-SCID mice which have 
the HIV-1-infected MDM injected into the basil ganglia thus displaying most of 
the neuroinflammatory and neurotoxic responses there, HIV-Tat Tg mice carry 
the expression of Tat almost globally in CNS [96, 97]. Therefore, the spatial 
pattern of GLS1 dysregulation in HIV-Tat Tg mouse CNS is expected to be 
different from that in HIVE-SCID mouse CNS. Our previous data revealed that 
the majority of GLS1 aberrant upregulation in HIVE-SCID mouse CNS was 
found in neurons of the inflammatory area [53]. One study reported that the 
neuronal damage is largely localized in the cerebellum and cortex of HIV-Tat Tg 
mouse [101]. Other studies reported relatively subtle neural damages including 
reductions in spine density and malformations of dendrites of neurons [106]. It is 
important to locate the specific cell type and possibly the specific brain area that 
has the majority of GLS1 dysregulation in HIV-Tat Tg mouse.  
Besides the spatial profile of GLS1 dysregulation, to know the temporal 
regulation profile of GLS1 in HIV-Tat Tg mouse is equally important. This will 
help to determine the sequence of inflammatory and neurotoxic events occuring 
in HIV-Tat Tg mouse brain. It is interesting to know whether the aberrant 
upregulation of GLS1 occurs prior to brain inflammatory responses. This will be 
critical to determine the pathogenic role of GLS1 dysregulation in HAND. It could 
be challenging to distinguish sequence of events as multiple events could have 
occurred within a very short time frame thus making it difficult for investigators to 
tell them apart. In consideration of this, using genetical tools to modify GLS1 
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regulation in mouse CNS will be a helpful approach towards the determination of 
the cause-effect relationship. 
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2.6 Tables and Figures 
TAT 1 GCGGATCCATGGAGCCAGTAGATCCTAG 
TAT 2 GCGAATTCTCATTGCTTTGATAGAGAAACTTG 
RTTA 1 AATCGAAGGTTTAACCCG 
RTTA 2 TTGATCTTCCAATACGCAACC 
 
Table 2.1 Primers used for the genotyping of HIV-Tat Tg mouse. Two 
sets of primers were used to determine the genotype of HIV-Tat Tg mouse. TAT 
1 and TAT 2 were used to determine the presence of Tat gene. RTTA 1 and 
RTTA 2 were used to determine the presence of the doxycyline-inducible control 
of the promoter. 
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Figure 2.1 HIV-Tat Tg mice had upregulated GLS1 isoforms KGA and 
GAC in the brain. A-B). Whole brain lysates from HIV-Tat Tg and their WT 
control littermates were collected and the expression levels of KGA and GAC 
were determined by Western blot. Representative blots of GAC expression are 
shown (A). Quantification data were normalized to beta-actin and presented as 
fold changes compared to control mice (B). C). Intracellular glutamate levels of 
whole brain lysates were determined using the Amplex Red Glutamic acid / 
Gutamate oxidase Assay Kit. Data are shown as the means ± SEM. * P < 0.05,   
compared with control mice, N = 6 for WT controls and HIV-Tat Tg mice.  
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Figure 2.2 HIV-Tat Tg mice had increased astrogliosis in correlation 
with the upregulation of GLS1 and elevation of brain glutamate. A-B). 
Whole brain lysates from HIV-Tat Tg and their WT control littermates were 
collected and the expression levels of GFAP were determined by Western blot. 
Representative blots of GFAP expression are shown (A). Quantification data 
were normalized to beta-actin and presented as fold changes compared to 
control mice (B). C-E). Correlations of KGA protein levels (C), GAC protein 
levels (D), brain glutamate levels (E) with GFAP protein levels were determined 
by Spearman correlation. 
 
 
  36 
 
 
Figure 2.3 HIV-Tat Tg mice exhibited impairment in spatial learning 
and memory. A-D). Morris-Water-Maze test was utilized to examine the spatial 
learning of memory of HIV-Tat Tg mice. During the training phase, HIV-Tat Tg 
mice exhibited longer escape latency (A), travelled longer distance to reach 
platform (B), but exhibited similar swimming velocities (C). During probe test, 
HIV-Tat Tg mice spent less time in the target quadrant (D). Data are shown as 
the means ± SEM. * P < 0.05, *** P < 0.001, compared with control mice, N = 6 
for WT controls and HIV-Tat Tg mice.  
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Figure 2.4 HIVE-SCID mice exhibited impairment in spatial learning 
and memory. A-B). Morris-Water-Maze test was utilized to examine the spatial 
learning of memory of HIVE-SCID mice. During the training phase, HIVE-SCID 
mice exhibited longer escape latency (A). During probe test, HIVE-SCID mice 
spent significantly less time in the target quadrant (B). Data are shown as the 
means ± SEM. * P < 0.05, *** P < 0.001, compared with control mice, N = 6 for 
uninfected-MDM controls and HIVE-SCID mice.  
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Figure 2.5 GLS1 and glutamate levels were in correlation with MWM 
performances of HIV-Tat Tg mice. A-D). Correlations of KGA protein levels 
(A), GAC protein levels (B), brain glutamate levels (C) with the escape latencies 
(A-C) on the last day of MWM training phase and the times that mice spent in 
Q2 (D) of MWM probe test were determined by Spearman correlation. Levels of 
significance are indicated in the figure. 
 











Brain-specific Overexpression of Glutaminase C Induces 
Neuroinflammation, Synaptic Damage and Dementia in Mice: Relevance to 
HAND 
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3.1 Abstract 
Glutaminase is the enzyme that converts glutamine into glutamate, which 
serves as a key excitatory neurotransmitter and one of the energy providers for 
cellular metabolism. Glutamate is essential for proper brain functioning but at 
excess levels, it is neurotoxic and has a key role in the pathogenesis of various 
neurodegenerative diseases, including HIV-1 associated neurocognitive 
disorders (HAND). However, the detailed mechanism of glutamate-mediated 
neurotoxicity remains unclear. Our previous data revealed upregulation of 
glutaminase C (GAC) in the postmortem brain tissues of patients with HIV 
dementia by protein analysis, suggesting a critical role of GAC in the instigation 
of primary dysfunction and subsequent neuronal damage in HAND. Therefore, 
we hypothesize that GAC dysregulation in brain is sufficient to induce brain 
inflammation and dementia in relevance to HAND. Using a brain GAC 
overexpression mouse model (which has the overexpression of GAC confined in 
the brain), we found that the expression of the marker for brain inflammation, the 
glial fibrillary acidic protein (GFAP), was increased in the brains of GAC-
overexpression mice, suggesting increased reactive astrogliosis. To study the 
functional impact of GAC overexpression, we performed Morris Water Maze 
(MWM) test and Contextual Fear Conditioning (CFC) test to determine the 
learning and memory of mice. GAC-overexpression mice exhibited longer 
escape latency during the training and lower percentage of time spent in the 
target quadrant during the probe test, indicating that overexpressing GAC in 
mouse brain impaired the learning and memory of the animals. Together, these 
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data suggest that dysregulated GAC in mouse brain causes prolonged 
inflammation and dementia.  
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3.2 Introduction 
        Neurological disorders develop during progressive HIV-1 infection and are 
characterized by cognitive deteriorations, behavioral disorders and potential 
progressive motor impairments as a consequence of neuronal damage [107]. 
These disorders affect up to 50% of HIV-1 infected individuals and are termed 
as HIV-1 associated neurocognitive disorders (HAND) [3]. HAND comprise three 
categories based on standardized measures of dysfunction [2]: HIV-1 
associated dementia (HAD), minor cognitive motor disorder (MCMD), and 
asymptomatic neurocognitive impairment (ANI) [2]. With the effective treatment 
by highly active antiretroviral therapy (HAART), the occurrence of HAD, the 
most severe and devastating form of HAND, has dramatically fallen [4]. 
However, HAART fails to prevent the milder neurocognitive disorders, thus 
cognitive impairment continues to be a commonplace associated with HIV-1 
infection. It is critical to develop new therapeutic approaches to prevent 
neurocognitive impairment, as it is affecting the everyday life of patients 
including driving, employment and medication management.        
         Chronic neuroinflammation is a hallmark of HAND and a constitutive 
component of the pathogenesis of neurodegenerative diseases including HAND, 
multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease and 
Alzheimer’s disease [33-35]. Literature have suggested a close link between 
brain inflammation and neuronal injury [36, 39]. HIV-infected and activated 
microglia or macrophages instigate brain inflammation and induce neuronal 
injury through the production and release of various soluble neurotoxic factors 
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including glutamate [51, 52, 108]. Apart from glia cells, neurons play a role in the 
progress of brain inflammation as well. Specifically, proinflammatory cytokines 
TNF-α and IL-1β, which are typically elevated during neurodegenerative 
diseases, induced neuronal loss via the production and release of glutamate in 
neuronal culture [53].   
        Glutamate is the most abundant neurotransmitter in CNS [55]. It is 
essential for vital physiologic processes including neural development, synaptic 
plasticity, learning and memory [56, 57]. However at excess levels, glutamate 
has the potential to induce extensive neuronal injury, which is termed 
excitotoxicity. Therefore, elevated glutamate has been linked to the pathogenic 
processes of various CNS disorders [65-68] and neurodegenerative diseases  
including HAND [50, 69, 70]. In CNS, glutamate is typically derived from 
glutamine by the action of mitochondrial enzyme glutaminase. The predominant 
glutamine-utilizing and glutamate-producing enzyme in CNS is glutaminase 1 
(GLS1), whereas the isozyme glutaminase 2 is expressed at lower levels [72]. 
Furthermore, GLS1 has two alternative splicing isoforms, which include 
glutaminase C (GAC) and kidney-type glutaminase (KGA). GAC shares the 
same functional region of KGA and possesses a unique C-terminal [76]. 
Glutaminase catalyzes the following reaction: Glutamine + H2O → Glutamate + 
NH3. This reaction is energetically favorable so glutaminase must be tightly 
regulated to prevent excess glutamate generation and excitotoxicity [73]. In the 
past decade our laboratory developed molecular and chemical tools with explicit 
intent to understand glutaminase activity and functions in the brain. Along with 
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others, we have documented roles of GLS1 in microglia and macrophages in 
brain injury, infection and inflammation [50, 84, 85] and more recently the 
regulation and function of GLS1 in neurons [53]. Importantly, we have identified 
a specific upregulation of GAC levels in the postmortem brain tissue of HAND 
patients [84, 90], suggesting that GAC might play a pathogenic role in HAND.  
The currently available murine models for HAND include: HIV-1 
glycoprotien 120 (gp120) transgenic mouse, HIV-Tat transgenic mouse, the 
humanized mouse, and the HIV-1 encephalitis (HIVE) mouse [94]. While all 
these models contribute to revealing the neuropathology of HAND, none of them  
study the role of glutaminase. In order to unravel it, we generated a brain GAC 
overexpression mouse model (which has the GAC overexpression confined in 
the brain) and found prolonged brain inflammation and dementia in brain-
specific GAC overexpression animals.   
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3.3 Materials and methods 
Generation of CAG-loxp-GAC and Nestin-GAC mice 
The mouse Gac gene was cloned from a C57 mouse cDNA library and 
was inserted into the pCAG-Loxp-STOP-Loxp-IRES-LacZ plasmid at restriction 
enzyme site XhoI. The constructed plasmid was sequenced to ensure that only 
plasmids with Gac forwardly inserted. The selected plasmid was linearized and 
the linearized plasmid was microinjected into the fertilized egg for implantation 
into a pseudopregnant female to create CAG-loxp-GAC mouse in the Mouse 
Genome Engineering Core Facility of UNMC. GFP expressions in the brains of 
CAG-loxp-GAC mice were examined to ensure the stable expressions of the 
constructed plasmid. The CAG-loxp-GAC mice were then mated with a nestin 
promoter-driven cre transgenic mouse (Nestin-Cre mouse) line (in which the cre 
activity is confined to CNS) [109] to produce Nestin-GAC mice (Figure 3.1).  
Animals 
Nestin-Cre mice of four weeks of age were purchased from Jackson 
Laboratory (Bar Harbor, ME). All mice were housed and bred in the 
Comparative Medicine facilities of the University of Nebraska Medical Center. All 
procedures were conducted according to protocols approved by the Institutional 
Animal Care and Use Committee of the University of Nebraska Medical Center. 
All transgenic mice were genotyped through PCR reactions. DNA of embryonic 
tissue or adult mouse-tail tissue was extracted with phenol/chloroform, and 
purified by isopropanol and ethanol for PCR reactions. The primers used for 
genotyping are listed in Table 3.1. 
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Morris Water Maze (MWM) test 
MWM test consists two parts, the training phase and probe test. Mice 
were introduced into a circular, water-filled tank, 91 cm in diameter and 110 cm 
in height. The tank was equally divided into four quadrants. Visual cues were 
placed around the pool in plain sight of the mouse to flag the submerged 
platform (10 cm in diameter). Various parameters of mouse movement were 
recorded, including the time spent in each quadrant of the pool, the time taken 
to reach the platform (escape latency), and the total distance traveled.  For each 
trial, the mouse was allowed no more than 60 seconds to find the submerged 
platform before they were guided to the platform, removed from water, towel 
dried and returned to their cage. Each mouse will complete 4 trials per day 
during the 5-day training phase. Immediately after the training, the probe test 
was conducted. For the probe test, the platform was removed and each mouse 
was still given 60 seconds to swim in the water. The swimming was videotaped 
analyzed by Ethovision XT (Noldus, Netherlands).  
Contextual Fear Conditioning (CFC) Test 
Fear conditioning was performed following standard procedures in the 
light- and sound-attenuated chambers for mouse (Coulbourn Tru Scan Activity 
Monitoring System for mouse). Mouse behavior was evaluated under ambient 
illumination (room light) and was recorded by a SAMSUNG digital videocamera 
set above the mouse arena chamber. The recorded behavior videos were 
analyzed by Ethovision XT (Noldus), which assesses the time of freezing by 
measuring changes in pixel intensities of video frames. The fear conditioning 
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procedure was conducted over 3 days. On 1st day, mice were given 300 
seconds to be habituated to the arena chamber and no shock was administered. 
The mouse chamber was cleaned with 70% ethanol before the introduction of 
each mouse to the arena chamber. On 2nd day, the mouse chamber was 
scented with 0.1% acetic acid and the mice were given two electric shocks at 
170 s and 290 s during the 300 s through the automated Tru Scan Stimulus. 
Chamber was cleaned with a non-alcohol disinfectant. On 3rd day, the chamber 
was also scented with 0.1% acetic acid but no shock was given. Mice in the 
mouse chamber were recorded for 180 s on the third day. The mouse chamber 
was cleaned with a non-alcohol disinfectant. The freezing behavior was 
analyzed by Ethovision XT (Noldus) and the percent of freezing was calculated 
for each day.  
Tissue protein extraction and Western-blot 
The animals were sacrificed and the brains were removed. The 
hippocampi, cortices, striatum, and kidneys were dissected free. The dissected 
tissues were homogenized by M-PER Protein Extraction Buffer (Pierce, 
Rockford, IL) containing 1× protease inhibitor cocktail (Roche). Protein 
concentrations were determined using a BCA Protein Assay Kit (Pierce). 
Proteins (5-10 µg) from tissue lysates were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoretic 
transfer to polyvinyldifluoridene (PVDF) membranes (Millipore and Bio-Rad), 
proteins were treated with purified primary antibodies for MAP-2 (mouse, 
cat#MAB3418, Millipore, 1:1000), GAC (rabbit, Dr. N. Curthoys, Colorado State 
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University, 1:500), Synaptophysin (rabbit, cat#ab32127, Abcam, 1:25,000), 
GFAP (mouse, cat#3670S, cell signaling, 1:1000), PARP (rabbit, cat# 9542s, 
Cell Signaling Technologies, Beverly, MA, 1:1000), Caspase 3 (rabbit, 
cat#9662s, Cell Signaling, 1:1000) or β-actin (Sigma-Aldrich) overnight at 4 oC 
followed by a horseradish peroxidase-linked secondary anti-rabbit or anti-mouse 
antibody (Cell Signaling Technologies, 1:10,000).  Antigen-antibody complexes 
were visualized by Pierce ECL Western Blotting Substrate (Pierce). For data 
quantification, films were scanned with a CanonScan 9950F scanner; the 
acquired images were then analyzed on a Macintosh computer using the public 
domain NIH Image J program (at http://rsb.info.nih.gov/nih-image/).       
Free-floating immunohischemistry and image analyses 
Animals were sacrificed and perfused with phosphate-buffered saline 
(PBS) and then with depolymerized 4% paraformaldehyde (PFA). The brains 
were rapidly removed and immersed in freshly depolymerized 4% PFA for 48 
hours and then cryoprotected by 30% sucrose for 48 hours. The fixed, 
cryoprotected brains were frozen and sectioned in the coronal plane at 30 µM 
using a Cryostat (Leica Microsystems Inc., Bannockburn, IL), with sections 
collected serially in PBS as previously described [110]. Brain sections were then 
incubated overnight at 4 oC with primary antibodies, followed by goat anti-mouse 
IgG Alexa Fluor 488 secondary antibodies (Molecular Probes, Eugene, OR, 
1:1000) for 1 hour at 25 oC. Primary antibodies included rabbit GLS1 (Dr. N. 
Curthoys, Colorado State University, 1:500), rabbit Synaptophysin (Abcam, 
cat#ab32127, 1:500), and rabbit GFAP (Dako, Carpinteria CA, 1: 2000). All 
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antibodies were diluted in 0.1% Triton X-100, 5% goat serum in PBS. Cells were 
counterstained with DAPI (Sigma-Aldrich, 1:1000) to identify nuclei. Images 
were taken using a Zeiss Meta 710 confocal microscope (Carl Zeiss 
MicroImaging, LLC) (20X object, tile scan 4X4 mode). Eight brain section 
images from three mice were imported into Image-ProPlus, version 7.0 (Media 
Cybernetics, Silver Spring, MD) for quantifying levels of either GFAP / DAPI, or 
Synaptophysin / DAPI double positive staining.  
In situ TUNEL assay 
Brain sections were stained with an in situ TUNEL assay (Roche 
Diagnostics, Indianapolis, IN) according to the manufacturer’s protocol. The 
fluorescence intensity of TUNEL was quantified after acquiring random images 
from immunostained fields using a Nikon Eclipse TE2000E microscope. Eight 
brain section images from four mice were imported into Image-ProPlus, version 
7.0 (Media Cybernetics, Silver spring, MD) for quantifying levels of fluorescence 
intensity.  
Hippocampal electrophysiology 
Mouse hippocampal electrophysiology was perfomed as previously 
described [111, 112]. mouse hippocampi were dissected free and live sagittal 
hippocampal slices (300 µM in thickness) were prepared using a tissue chopper. 
The hippocampal slices were incubated in the artificial cerebrospinal fluid 
(ACSF, containing 124mM NaCl, 26mM NaHCO3, 1.25 mM NaH2PO4, 2.5 mM 
KCl, 2 mM CaCl2, 2 mM MgCl2, and 10 mM glucose equilibrated with 95% O2 
and 5% CO2, pH 7.3-7.4). The temperature of the perfusate was maintained at 
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30 + 1 oC with an automatic temperature controller (Warner Instrument, 
Hamden, CT). The slices were incubated in the ACSF for 1-2 hours, and then 
transferred to a recording chamber mounted on the stage of a dissection 
microscope. Field excitatory postsynaptic potentials (fEPSPs) were evoked by a 
low-frequency orthodromic stimulation (0.05 Hz) with constant current of 
Schaffer collateral / Schaffer collateral commissural axons using an insulated 
(excluding the tip) bipolar tungsten electrode. The intensity of stimulation was 
selected to generate nearly 50% of a maximal response. The elicited fEPSPs 
were recorded with an Axopatch-1D amplifier (Axon Instruments, CA) in the CA1 
dendrites area (stratum radiatum). The recording microelectrodes were made 
from borosiliacate glass capillaries with inner filaments enabling quick 
backfilling. The diameter of the tip of the microelectrode was 5.0 µm with a 
resistance of 1-5 MΩ when filled by ACSF. 
The frequency facilitation tests were performed at 50% maximal fEPSP 
for each hippocampal slice. A stimulation burst consisting 10 pulses was applied 
to the slice after a 20 minute acclimation. The responses were recorded. Then 
the slice was given a 20 minute recovery time before another stimulation burst 
was given. The initial slopes of the recorded fEPSPs were measured and 
analyzed as the percent of the first pulse (taking the first as 100%). Recordings 
from the same group at the same time were averaged.  
The ability of the high-frequency stimulation (HFS: 100 Hz, 500msec X 2) 
to induce long-term potentiation (LTP) in CA1 of hippocampus was studied. The 
high-frequency stimulus (HFS) was delivered to each hippocampal slical after 
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the 30 minute baseline recording and LTP was evoked. The initial slopes of 
fEPSPs were measured and expressed as a percent of the baseline. LTP were 
determined at 45-55 minutes after HFS. 
Analyses of glutamate concentrations 
The intracellular glutamate levels in brain lysates of mice were 
determined by Amplex Red Glutamic acid / Gutamate oxidase Assay Kit 
(invitrogen) based on the manufacturer’s instruction. Brain tissue lysates were 
diluted to the same protein concentration before entering the assay.        
Statistical analyses 
Data were analyzed as means ± SEM. The data were evaluated 
statistically by the analysis of variance (ANOVA) followed by Tukey-test for 
pairwise comparisons by using GraphPad Prism software. The two-tailed 
Student’s t test was used to compare means of two groups. Correlations were 
determined by Spearman correlation. Significance was considered when P < 
0.05. All experiments were performed with at least three mice in each group to 
account for any individual animal-specific differences. Assays were performed at 
least three times in triplicate or quadruplicate. 
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3.4 Results 
GAC overexpression is specific to brains of Nestin-GAC mice 
Lysates from the whole brain and kidney of both Nestin-GAC mice and 
their wide-type (WT) control mice littermates prepared. Total protein was 
extracted from either the whole brain lysates or kidney lysates. The gene 
expression levels of GAC were determined by Western-blot and were found to 
be higher in the whole brain lysate of Nestin-GAC mice than that of WT control 
littermates (Figure 3.2A-B). Meanwhile, the total amount of intracellular 
glutamate in the whole brain lysates was measured. In parallel to the increase of 
GAC protein levels in the whole brain lysates of Nestin-GAC mice, the glutamate 
levels were found to be higher in Nestin-GAC mice brains than that in WT 
control littermates brains (Figure 3.2C), indicating higher enzymatic activity of 
glutaminase in Nestin-GAC mouse brains. In contrast to the differences of GAC 
protein levels in the whole brain lysates, Nestin-GAC mice and their WT control 
littermates were found to have similar protein expression levels of GAC in the 
kidney lysates (Figure 3.2D-E). Likewise, Nestin-GAC mice and their WT control 
littermates had similar amount of glutamate in the kidney lysates (Figure 3.2F). 
Therefore, these results demonstrate that the overexpression of GAC is specific 
to brains in Nestin-GAC mice. 
GAC overexpression is confirmed in different areas of Nestin-GAC 
mouse brain 
Whole brains of Nestin-GAC mice and their WT control littermates were 
dissected and protein lysates were prepared from the hippocampi, cortices, 
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midbrains and cerebellums. The expression levels of GAC in different areas of 
mouse brains were determined by Western-blot. Nestin-GAC mice had higher 
expression levels of GAC in hippocampal, cortical, midbrain and cerebellar 
lysates than that in lysates of WT control littermates (Figure 3.3A-B). In parallel 
to the increase of GAC protein levels in different areas of Nestin-GAC mouse 
brains, the amount of glutamate was found to be higher in hippocampal, cortical, 
midbrain and cerebellar lysates (Figure 3.3C), indicating increased glutaminase 
enzymatic activity in these brain areas of Nestin-GAC mice. To visualize the 
increase of glutaminase protein levels in hippocampi of Nestin-GAC mouse 
brains, we applied the anti-GLS1 antibody to brain slices of Nestin-GAC mice 
and their WT control littermates. The fluorescence intensities of GLS1 were 
quantified. Nestin-GAC mouse brain slices clearly had higher expression levels 
of GLS1 in hippocampi (Figure 3.3D-E). These results confirm that GAC is 
overexpressed in different areas of Nestin-GAC mouse brains. 
Nestin-GAC mice exhibited deficits in learning and memory 
To study the functional impact of the brain-specific GAC overexpression, 
we utilized MWM test and CFC test to study the learning and memory of Nestin-
GAC mice and their WT control littermates. During the training phase of MWM 
test, Nestin-GAC mice displayed longer escape latency (time spent to reach the 
escape platform) (Figure 3.4A) and travelled longer distance to escape (Figure 
3.4B), indicating that Nestin-GAC mice had impaired capabilities in learning to 
escape from water. Meanwhile, Nestin-GAC mice had similar swimming 
velocities comparing with that of WT control littermates (Figure 3.4C). This 
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demonstrates that the impairment of learning in Nestin-GAC mice is not due to 
deficits in motor functions. Likewise, Nestin-GAC mice spent significantly less 
time in the target quadrant (Q2, where the escape platform was during the 
training phase) in the probe test than that spent by WT control littermates 
(Figure 3.4D), and Nestin-GAC mice had significantly fewer times of crossings 
through the platform area (Figure 3.4E). These results indicate that Nestin-GAC 
mice are impaired in spatial learning and memory. Importantly, Nestin-GAC 
mice apparently had lower percentage of freezing than that of WT control 
littermates on the last day of CFC test (Figure 3.4F), indicating again that these 
mice are impaired in hippocampus-related memory. Together, these results 
demonstrate that Nestin-GAC mice have deficits in learning and memory related 
to hippocampal and cortical functions.  
 Brain-specific overexpression of GAC leads to synaptic damage in mice 
To identify ongoing changes in the hippocampi and cortices relating to 
memory impairment of Nestin-GAC mice, we examined the synaptic network in 
the brains of these animals. The expression levels of synapses marker, 
Synaptophysin, were determined by Western blot in the hippocampal and 
cortical lysates of Nestin-GAC mice and their WT control littermates. 
Interestingly, the expression levels of Synaptophysin were found to be 
dramatically decreased in the hippocampal (Figure 3.5A-B) and cortical (Figure 
3.5C-D) lysates of Nestin-GAC mouse brains compared to that of WT control 
littermates. This dramatic decrease indicates synaptic damage in the 
hippocampal and cortical neuronal network of Nestin-GAC mouse brains. To 
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visualize the changes of the expression levels of Synaptophysin, we applied the 
anti-Synaptophysin antibody to brain slices of Nestin-GAC mice and WT control 
littermates. The fluorescence intensity of Synaptophysin was quantified. 
Apparently, Nestin-GAC mice had lower expression levels of Synatophysin in 
hippocampus as implied by lower fluorescence intensity (Figure 3.5E-F). 
Together, these results suggest that the brain-specific GAC overexpression 
leads to hippocampal and cortical synaptic damage in mice. 
To determine whether synaptic injury leads to loss of hippocampal 
synaptic function, we recorded long-term potentiation (LTP) in the CA1 region of 
hippocampal brain slices. Nestin-GAC Tg mice exhibited diminished initiation 
and maintenance of LTP (Figure. 3.6A-B), indicating GAC overexpression leads 
to marked impairment of hippocampal synaptic transmission in vivo. 
Brain-specific GAC overexpression leads to increased apoptosis in 
mouse brains. 
To explore of the specific reasons that cause the synaptic network 
damage, we examined the expression levels of important proteins in the 
apoptosis cascade. The expression levels of activated Caspase 3 (cleaved-
Caspase 3) and cleaved-PARP were determined by Western blot. Interestingly, 
both the expression levels of cleaved-Caspase 3 and cleaved-PARP were found 
to be dramatically increased in the hippocampal (Figure 3.7A-B) and cortical 
(Figure 3.7C-D) lysates of Nestin-GAC mice compared to that of WT control 
littermates. This indicates that there is increased apoptosis ongoing in Nestin-
GAC mouse brains. Importantly, the number of TUNEL positive cells in the 
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hippocampus was found to be increased as well in brain slices of Nestin-GAC 
mice compared to WT control littermates as revealed by the in-situ TUNEL 
assay (Figure 3.7E-F). These results together suggest that there is increased 
ongoing apoptosis in the Nestin-GAC mouse hippocampi and cortices that may 
account for the synaptic network damage in these animals.  
Brain-specific GAC overexpression leads to reactive astrogliosis in 
mouse brains.  
Brain inflammation is a hallmark of HAND and a constitutive component 
in the pathogenesis of HAND. To identify whether there is existing brain 
inflammation of Nestin-GAC mice, we examined the expression levels of the 
astrogliosis marker, glial fibrillary acidic protein (GFAP), by western blot and 
immunohistochemistry. We found a significant increase of GFAP protein 
expressions in the hippocampal (Figure 3.8A-B) and cortical (Figure 3.8C-D) 
lysates of Nestin-GAC mice compared with that of WT control littermates. 
Consistently, the fluorescence intensity of GFAP was found to be significantly 
higher in hippocampi of Nestin-GAC mouse brain slices than that of WT control 
littermate brain slices (Figure 3.8E-F). These results suggest ongoing reactive 
astrogliosis in the Nestin-GAC mouse brains which implies prolonged brain 
inflammation of Nestin-GAC mice. 
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3.5 Discussion 
Despite the encouraging progresses made by HAART, HAND is still 
significantly affecting the quality of life of HIV-1-infected individuals [3]. 
Identification of the key pathogenic components and understanding the 
mechanisms underlying the development of neurological disorders during HIV-1 
infection will largely contribute to the allevation, treatment or even prevention of 
cognitive deteriorations and behavioral disorders [107]. Despite the important 
discovery of the specific upregulation of GAC in the post mortem brain tissues of 
HAND patients and the implied association of GAC with the pathogenesis of 
HAND, the causal relationship of GAC upregulation and the disease 
progressions of HAND remains to be identified. In this chapter, we generate the 
Nestin-GAC transgenic mouse which has GAC overexpression confined in 
brain. We report that the brain-specific GAC overexpression results in learning 
and memory impairment in mice. Furthermore, we report that the brain-specific 
overexpression of GAC leads to hippocampal and cortical synaptic network 
damage, increased apoptosis and reactive astrogliosis in the hippocampi and 
cortices of mice. Importantly, we have observed impairment of LTP in Nestin-
GAC mice, further demonstrating for the synaptic damage in hippocampi of 
these animals. Together, these results suggest for the first time that the 
overexpressed GAC in brain has a causal relationship with prolonged brain 
inflammation and increased apoptosis, which, lead to neural network damage 
and finally result in the impairment of cognitive functions of animals.        
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The identification of the pathogenic role of GAC in HAND has an 
important clinical implication. Glutaminase dysregulation has long been 
implicated in the pathogenesis or pathology of HAND. However, this is the first 
time that we show that the dysregulation of the specific isoform of glutaminase 
1, GAC, in the brain may be one of the major components that cause HAND 
disease progressions through prolonged brain inflammation and increased 
apoptosis that then result in synaptic network damage. Hippocampal – cortical 
synaptic networking is well known to be essential for proper cognitive functions 
like learning and memory [113-121]. Hippocampal and hippocampal-cortical 
signaling has been studied for decades because of its crucial role in memory 
[121-131]. Among that, glutamate signaling is well known to affect synaptic 
plasticity [121, 127, 130, 132-134]. Specifically, a strong association between 
the memory loss due to aging or disease and the disruption of NMDA receptor-
mediated neurotransmission has been revealed [127, 130, 134]. Glutamate is an 
essential and vital neurotransmitter, but it is neurotoxic at excess levels. 
Because the reaction of deamination of glutamine to produce glutamate is 
energetically favorable, glutaminase as the primary enzyme catalyzing this 
reaction ought to be finely regulated to prevent excess production of glutamate. 
Although neighboring astrocytes of neurons are able to take up extra glutamate 
by glutamate transporters and convert it back to glutamine with the catalysis by 
glutamine synthase [81, 82], the present study suggests that the neural network 
damage caused by dysregulated GAC in the brain cannot be overcome.  
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Whether there are alterations or dysregulations of glutamate receptors in 
Nestin-GAC mouse brains is an interesting and important question to be 
answered. Excitotoxicity common to various neurodegenerative diseases  
including HAND involves overactivation of NMDA receptors. High-affinity NMDA 
receptor antagonist MK801 has successfully blocked the toxicity from neurons 
treated by inflammatory cytokines TNF-α and IL-1β [53]. More importantly, a 
low-to-moderate-affinity NMDA receptor antagonist memantine has substantially 
abrogated neurotoxicity and largely recovered the impaired synaptic 
transmission and LTP [111]. Determining whether or not the neurotoxicity 
observed in Nestin-GAC mouse brains is via the overactivation of NMDA 
receptors will greatly help to further validate the resemblance of Nestin-GAC 
mouse as a novel HAND murine model.  
Apart from glutamate receptors, to study whether there are alterations or 
dysregulations of glutamate transporters in Nestin-GAC mouse is of equal 
importance. Glutamate transporters are of prominence for glutamate uptake and 
regulating glutamate homeostasis [135]. Therefore, they serve as critical buffer 
against excitotoxicity in the brain. Previous studies have revealed that 
deregulation or loss of function of glutamate transporters EAAT1 and EAAT2 
located on astrocytes augments neural inflammation and neurotoxicity [136, 
137]. Enhancing EAAT1 activity is able to diminish neural damage and recover 
cognitive impairment [138, 139].   
Taken together, the study in this chapter suggests that dysregulated 
glutaminase under pathological conditions can be an important novel 
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therapeutic target for reversing HAND progressions and HAND-related 
complications. Because of that, to develop glutaminase inhibitors that target 
specific isoform of the enzyme and target specific cell types are one of the 
promising approaches for next step. Likewise, genetic approaches aiming to 
knock down the expression levels of glutaminase in specific types of cells have 
also been proposed as a promising therapeutic approach.  
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3.6 Tables and Figures 
GAC c GCTGTTAATGACCTGGGAACTG 
GAC d GTACCTCGAGCATCTCTAGCTCCTCTCCC 
Cre F GCGGTCTGGCAGTAAAAACTATC 
Cre R GTGAAACAGCATTGCTGTCACTT 
 
Table 3.1 Primers used for the genotyping of Nestin-GAC mouse. 
Two sets of primers were used to determine the genotype of Nestin-GAC 
mouse. GAC c and GAC d were used to determine the presence of Gac gene. 
Cre F and Cre R were used to determine the presence of Cre. 
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Figure 3.1 Schematic picture of Nestin-GAC mouse generation. The 
mouse Gac gene was cloned from a C57 mouse cDNA library and was inserted 
into the pCAG-Loxp-STOP-Loxp-IRES-LacZ plasmid at restriction enzyme site 
XhoI. The constructed plasmid was sequenced to ensure that only plasmids with 
Gac forwardly inserted. The selected plasmid was linearized and the linearized 
plasmid was microinjected into the fertilized egg for implantation into a 
pseudopregnant female to create CAG-loxp-GAC mouse in the Mouse Genome 
Engineering Core Facility of UNMC. GFP expressions in the brains of CAG-loxp-
GAC mice were examined to ensure the stable expressions of the constructed 
plasmid. The CAG-loxp-GAC mice were then mated with a nestin promoter-
driven cre transgenic mouse (Nestin-Cre mouse) line (in which the cre activity is 
confined to CNS) to produce Nestin-GAC mice. 
 
  63 
Figure 3.2 GAC overexpression was specific to brain in Nestin-GAC 
mice. A-B). Whole brain lysates from Nestin-GAC and their control littermates 
were collected and the expression levels of GAC were determined by Western 
blot. Representative blots of GAC expression are shown (A). Quantification data 
were normalized to beta-actin and presented as fold changes compared to 
control mice (B). C). Intracellular glutamate levels of whole brain lysates were 
determined using the Amplex Red Glutamic acid / Gutamate oxidase Assay Kit. 
D-E). Protein lysates from kidneys were collected and the expressions of GAC 
were determined by Western blot. Representative blots of kidney GAC 
expressions are shown (D). Quantification data were normalized to beta-actin 
and presented as fold changes compared to control mice (E). F). Intracellular 
glutamate levels of kidney lysates were tested using the Amplex Red Glutamic 
acid / Gutamate oxidase Assay Kit. Data are shown as the means ± SEM. * P < 
0.05, ** P < 0.01,  compared with control mice, N = 4.  
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Figure 3.3 GAC overexpression was confirmed in different areas of 
Nestin-GAC mouse brain. A-B). Proteins lysates were prepared from different 
areas of mice brains and the expression levels of GAC were determined by 
Western blot. Representative blots are shown (A). Quantification data were 
normalized to beta-actin and presented as fold changes compared to control 
mice (B). C). Intracellular glutamate levels of dissected brain tissues were tested 
using the Amplex Red Glutamic acid / Gutamate oxidase Assay Kit. D-E). The 
expression levels of GLS1 in hippocampi were visualized by 
immunofluorescence. Representative pictures are shown (D) and the GLS1 
fluorescence intensities were quantified (E). Data are shown as the means ± 
SEM. * P < 0.05, ** P < 0.01, *** P < 0.001  compared with control mice, N = 4 
for Nestin-GAC and control mice.  
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Figure 3.4 Nestin-GAC mice exhibited impairments in learning and 
memory. A-E). Morris-Water-Maze test was utilized to examine the spatial 
learning of memory of Nestin-GAC mice. During the training phase, Nestin-GAC 
mice exhibited longer escape latency (A), travelled longer distance to reach 
platform (B), but exhibited similar swimming velocities (C). During probe test, 
Nestin-GAC mice spent less time in the target quadrant (D) and had fewer 
crossings of the target place (E). F). Cued-Fear-Conditioning test was utilized to 
examine memory of Nestin-GAC mice. Nestin-GAC mice displayed lower 
percentages of freezing on last day of the test. Data are shown as the means ± 
SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, compared with control mice, N = 9 
for control, N = 7 for Nestin-GAC. 
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Figure 3.5 Brain-specific GAC overexpression led to synaptic 
damage in mice. A-D). Expression levels of synaptic marker Synaptophysin 
(Synap) were determined by Western blot. Nestin-GAC mice exhibited 
decreased protein levels of Synap in hippocampus (A, B) and in cortex (C, D). 
E-F). Expression levels of Synaptophysin in hippocampus were visualized and 
analyzed by immunofluorescence. Representative pictures are shown (E) and 
the fluorescence intensities of Synaptophysin were quantified (F). Data are 
shown as means ± SEM of 3 brain slices in each of the 4 control or Nestin-GAC 
mice. * P < 0.05, ** P < 0.01, *** P < 0.001, compared with control mice, N = 4 
for both Nestin-GAC and control mice.
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Figure 3.6 Nestin-GAC mice showed marked reduction in LTP. A-B). 
Hippocampi of Nestin-GAC mice were recorded for evoked fEPSPs by stimulus 
bursts and fEPSPs evoked by HFS. Data points represent means ± SEM of 10 
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Figure 3.7 Brain-specific GAC overexpression increased apoptosis 
in mouse brain. A-F). Expression levels of apoptosis marker cleaved-PARP (c-
PARP) and cleaved Caspase 3 (c-Cas) were determined by Western blot. 
Nestin-GAC mice exhibited increased protein levels of c-PARP and c-Cas in 
hippocampus (A, B, C) and in cortex (D, E, F). G-H). TUNEL positive cells in 
mice hippocampi were visualized and analyzed. Representative pictures are 
shown (G) and the fluorescence intensities of TUNEL were quantified (H). Data 
are shown as the means ± SEM of 3 brain slices in each of the 4 control or 
Nestin-GAC mice. * P < 0.05, ** P < 0.01, *** P < 0.001, compared with control 
mice, N = 4 for both Nestin-GAC and control mice.
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Figure 3.8 Brain-specific GAC overexpression led to reactive 
astrogliosis in mice. A-D). Expression levels of astrocyte marker GFAP were 
analyzed by Western blot. Nestin-GAC mice exhibited increased levels of GFAP 
in hippocampus (A, B) and in cortex (C, D). E-F). The expressions of GFAP in 
mice hippocampi were visualized and analyzed by immunofluorescence. 
Representative pictures are shown (E) and the fluorescence intensities of GFAP 
were quantified (F). Data are shown as the means ± SEM of 3 brain slices in 
each of the 4 control or Nestin-GAC mice. * P < 0.05, ** P < 0.01, compared 
with control mice, N = 4. 
 
 










GLS1 is Essential for the Differentiation, Survival and Proliferation of 
Human Neural Progenitor Cells 
Portions of this chapter are excerpted from STEM CELLS AND 
DEVELOPMENT, Nov. 15, 2014, pp. 2782-2790 
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4.1 Abstract 
Glutaminase is the enzyme that converts glutamine into glutamate, which 
serves as a key excitatory neurotransmitter and one of the energy providers for 
cellular metabolism. Previous studies have revealed that dysregulation of 
glutaminase 1 (GLS1), the dominant isoform in brain and kidney, has a causal 
effect on brain inflammation, neurotoxicity, and cognitive impairment. Therefore, 
we hypothesize that knocking down GLS1 will reduce toxicity and moderate the 
pathogenic progress. Using a human neural progenitor cell (NPC) model, we 
found that both GLS1 isotypes, kidney-type glutaminase (KGA) and glutaminase 
C (GAC), were upregulated during neuronal differentiation, which were 
correlated with the expression of neuronal marker microtubule-associated 
protein 2 (MAP-2). To study the functional impact of GLS1, we used small 
interference RNA targeting GLS1 and determined the expressions of neuronal 
genes by Western blot, Real-time PCR and immunocytochemistry. However, 
siRNA silencing of GLS1 significantly reduced the expression of MAP-2, 
indicating that GLS1 is essential for neurogenesis. To unravel the specific 
process(es) of neurogenesis being affected, we further studied the proliferation 
and survival of NPCs in vitro. siRNA silencing of GLS1 significantly reduced the 
Ki67+ and increased the TUNEL+ cells, suggesting a critical roles of GLS1 for 
the proliferation and survival of NPCs. Together, these data suggest that GLS1 
is critical for proper functions of NPC, including neuronal differentiation, 
proliferation, and survival, thus complete knockdown of GLS1 in CNS to reduce 
toxicity is not applicable.  
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4.2 Introduction 
Neural stem/progenitor cells (NPCs) are multipotent self-renewal cells 
with the capabilities of differentiation into neurons, astrocytes, and 
oligodendrocytes [140]. Neurogenesis, the process by which new neurons are 
generated, is a coordination of NPC self-renewal, survival, migration, 
proliferation, cell fate commitment, neuronal differentiation, and finally the 
integration of the newborn neurons into the existing networks [141, 142]. 
Neurogenesis is vigorous throughout embryonic brain but confined to specific 
brain areas in adulthood [142-144]. Attenuated neurogenesis leads to brain 
malformations, disruption of neural signal transduction and cognitive impairment 
[145-147]. This suggests that neurogenesis is indispensable to brain 
development, homeostasis and activity. Restricted neurogenesis in the adult 
brain has posted a big challenge for the brain regeneration after injuries, 
damage and diseases [148-153]. Therefore, extensive research is being 
conducted to identify endogenous factor(s) involved in neurogenesis.  
Glutaminase 1 (GLS1) is an enzyme that catalyzes the deamination of 
glutamine to produce glutamate [154]. In the central nervous system (CNS), 
glutaminase 1 (GLS1) is expressed at predominant levels, especially in neurons 
[74] when compared with GLS2 [72]. In mouse, GLS1 begins to express at 
embryonic day 11.5 (E11.5) revealed by in situ hybridization 
(http://developingmouse.brain-map.org/gene/show/14436). The expression of 
GLS1 gose higher during brain development and reaches the plateau before 
birth (at E18.5). GLS1’s expression remains high in postnatal mouse brain. 
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Kidney-type glutaminase (KGA) and glutaminase C (GAC) are two splice 
variants of GLS1 [76].  
The product of glutaminase-modulated glutamine deamination is 
glutamate, a classical and the most abundantly used excitatory 
neurotransmitter. Glutamate has long been implicated in the generation and 
maturation of neurons [155-158]. Particularly, in vitro study on NPC has 
revealed the crucial role of glutamate in neuronal differentiation via the 
mediation of AMPA receptors [157]. However, the in vivo effect of glutamate on 
neurogenesis remains incompletely understood. Glutamate has been indicated 
to be beneficial for neurogenesis [159, 160], but studies on different anatomical 
areas in mammalian brain and using different experimental approaches yielded 
discrepant results [155]: moderate dose of glutamate (50 µM) applied to mouse 
brain slice cultures increased cellular proliferation in the ventricular zone but 
decreased NPC proliferation in the subventricular zone [158]. However, high 
dose of glutamate (300 µM) applied to brain slice culture decreased cellular 
proliferation and survival in the ventricular zone [159].  
Our previous data revealed a pathogenic role of overexpressed brain 
GLS1 in brain inflammation, neurotoxicity and cognitive impairment. Thus we 
hypothesize that by knocking down GLS1 in the brain cells we will be able to 
reduce brain inflammation and reduce neurotoxicity. However  in this study, we 
report that GLS1 is an essential enzyme for the neuronal differentiation, 
proliferation, and survival of human neural progenitor cells in vitro, thus 
complete knockdown of GLS1 in the brain is not applicable. 
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4.3 Materials and methods 
Culture of human NPC 
Human fetal brain tissue (12-16 weeks post-conception) was obtained 
from elective abortions done at the  University of Washington in complete 
compliance with National Institute of Health (NIH), University of Nebraska 
Medical Center (UNMC) and University of Washington ethical guidelines. 
Human cortical NPCs were isolated from human fetal brain tissue as previously 
described [161]. Briefly, isolated NPCs were cultured in substrate-free tissue 
culture flasks and grown to neurospheres in the neurosphere initiation medium 
(NPIM), which is composed of X-Vivo 15 (BioWhittaker, Walkersville, ME) with 
N2 supplement (Gibco BRL, Carlsbad, CA), neural cell survival factor-1 (NSF-1, 
Bio Whittaker), basic fibroblast growth factor (bFGF, 20 ng/ml, Sigma-Aldrich, 
St. Louis, MO), epidermal growth factor (EGF, 20 ng/ml, Sigma-Aldrich), 
leukemia inhibitory factor (LIF, 10 ng/ml, EMD Millipore Corporation, Billerica, 
MA), and 60 ng/ml N-acetylcysteine (Sigma-Aldrich). Cells were passaged every 
two weeks as previously described [161]. 
Neuronal differentiation of NPC 
Differentiation of NPCs to neurons was performed according to the 
standard procotol as previously described [161]. Briefly, mechanically- and 
trypsin-dissociated NPCs were plated on poly-D-lysine-coated 24-well plates in 
NPIM for 24 hours. Cells were then changed to serum-free Neurobasal medium 
(Gibco BRL) supplemented with B27 (NB27 medium, Gibco BRL) and glutamine 
(Sigma-Aldrich). Cells were subsequently collected for RNA or protein analyses, 
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or fixed for immunocytochemistry after neuronal differentiation for specific days 
as indicated in the figure legends. 
siRNA silencing of GLS1 
siRNA silencing of GLS1 in NPCs was performed according to the 
standard protocol as previously described [162]. Briefly, siRNA targeting GLS1 
(ID# s5840) was purchased from Applied Biosystems Inc. (Foster City, CA, 
USA). Before plated-NPCs were changed into serum-free Neurobasal medium 
for neuronal differentiation, cells were transfected by 100 nM siRNA duplexes 
for 24 hours with the presence of siIMPORTER (Upstate Cell Signaling 
Solutions, Charlottesville, VA) according to the manufacturer’s instructions. Non-
specific control siRNA from Applied Biosystems Inc. (ID# AM4635) was 
transfected with the same concentration as controls to GLS1 siRNA. 
Protein extraction and Western blot 
Cells were rinsed twice with 1 X PBS and subsequently lysed by M-PER 
Protein Extraction Buffer (Pierce, Rockford, IL) containing 1× protease inhibitor 
cocktail (Roche). Protein concentrations were determined by the BCA Protein 
Assay Kit (Pierce). Proteins (20-30 µg) from cell lysates were separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After 
being electrophoreticly transferred to the polyvinyldifluoridene (PVDF) 
membranes (Millipore and Bio-Rad), proteins were incubated with purified 
primary antibodies for MAP-2 (mouse, cat#MAB3418, Millipore, 1:1000), KGA 
(rabbit, Dr. N. Curthoys, Colorado State University, Fort Collins, CO, 1:1000), 
GAC (rabbit, Dr. N. Curthoys, Colorado State University, 1:500), GAD67 
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(mouse, cat#MAB5406, Millipore, 1:500), PARP (rabbit, cat# 9542s, Cell 
Signaling Technologies, Beverly, MA, 1:1000), or β-actin (Sigma-Aldrich) 
overnight at 4 oC followed by a horseradish peroxidase-linked secondary anti-
rabbit or anti-mouse antibody (Cell Signaling Technologies, 1:10,000). Antigen-
antibody complexes were visualized by Pierce ECL Western Blotting Substrate 
(Pierce). For data quantification, films were scanned with a CanonScan 9950F 
scanner; the acquired images were then analyzed on a Macintosh computer 
using the public domain NIH Image J program (at http://rsb.info.nih.gov/nih-
image/). 
RNA extraction and TaqMan real-time quantitative RT-PCR 
RNA was extracted with TRIzol Reagent (Invitrogen Corp, Carlsbad, CA, 
USA) and RNeasy Kit according to the manufacturer’s protocol (Qiagen Inc., 
Valencia, CA, USA). Primers used for real-time reverse-transcription 
polymerase chain reaction (real-time RT-PCR) were KGA (ID# 489954: forward 
sequence 5-CGAAGATTTGCTTTGTCAGCTATGG-3, reverse sequence 5-
CTCTGCAGCAGCTACATGGA-3, probe sequence 5- 
CAGCGGGACTATGATTC-3), GAC (ID# 528445: forward sequence 5-
TATGGAAAAAAGTGTCACCTGAGTCA-3, reverse sequence 5-
GCTTTTCTCTCCCAGACTTTCCATT-3, probe sequence 5’-
AATGAGGACATCTCTACAACTGTA-3), microtubule-associated protein 2 
(MAP-2) (ID# hs00258900) and GAPDH (ID# 4310884E) were commercially 
available at Applied Biosystems Inc. Real-time RT-PCR was completed using 
the One-step quantitative TaqMan assay in a StepOneTM Real-Time PCR 
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system (Applied Biosystems Inc.). Relative MAP-2, KGA and GAC mRNA levels 
were determined and standardized with a GAPDH internal control using the 
comparative ∆∆CT method. All primers used in the study were previously tested 
for amplification efficiencies and the results were confirmed similar.  
Immunocytochemistry 
Cells were fixed in 4% PFA and washed in PBS as previously described 
[161]. Cells were subsequently incubated overnight at 4 oC with primary 
antibodies, followed by goat anti-mouse IgG Alexa Fluor 488 secondary 
antibodies (Molecular Probes, Eugene, OR, 1:1000) for 1 hour at room 
temperature. Primary antibodies included mouse MAP-2 (Millipore, 1:500), 
rabbit GFAP (Dako, Carpinteria CA, 1: 2000) and mouse anti-Ki67 (BD 
Biosciences, San Diego, CA, 1:500). All of the antibodies were diluted in in PBS 
containing 0.1% Triton X-100 and 2% BSA. Cells were counterstained with DAPI 
(Sigma-Aldrich, 1:1000) to identify the nuclei. Morphological changes of cells 
were visualized and captured with a Nikon Eclipse E800 microscope equipped 
with a digital imaging system, or a Zeiss META 510 confocal microscope (Carl 
Zeiss MicroImaging, LLC). Images were imported into Image-Pro Plus, version 
7.0 (Media Cybernetics, Sliver Spring, MD) for quantification purpose. A total of 
500-1000 immunostained cells from 10 random fields per well were manually 
counted using magnifications of 20X objective lens. 
Glutamate analyses 
The glutamate levels in the cells were determined using the Amplex Red 
Glutamic acid / Gutamate oxidase Assay Kit (invitrogen) based on the 
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manufacturer’s instruction. Cell lysates were diluted to the same protein 
concentration before starting the assay. 
In situ TUNNEL assay 
Primary human NPCs were transfected by control siRNA or GLS1 siRNA. 
Three days after transfection, cells were fixed and stained with an in situ TUNEL 
assay (Roche Diagnostics, Indianapolis, IN). TUNEL positive NPCs and total 
cell numbers were counted after acquiring 10 random images from 
immunostained fields using a Nikon Eclipse TE2000E microscope. A minimum 
of 10 fields was counted for each group of treatment. 
Statistical analyses 
Data were shown as means ± SEM and analyzed. The data were 
evaluated statistically by the analysis of variance (ANOVA) followed by Tukey-
test for pairewise comparisons. Two-tailed Student’s t test was used to compare 
means of two treatment groups. Significance was considered when P < 0.05. All 
experiments were performed with at least three donors to account for any 
individual-specific differences. Assays were performed at least three times in 
triplicate or quadruplicate. 
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4.4 Results 
GLS1 variants KGA and GAC are upregulated after neuronal 
differentiation 
Human NPC were differentiated to neurons in adherent cultures for 2 
weeks. Total protein and RNA were extracted at multiple time points, including 
day 0, 4, 7 and 13 after differentiation. The mRNA levels of the neuronal marker 
MAP-2 continued to increase throughout this period of time (Figure 4.1A), 
suggesting successful and continuous neuronal differentiation of the cultured 
cells. Interestingly, the mRNA levels of both KGA and GAC were upregulated 
during neuronal differentiation (Figure 4.1B-C). The mRNA levels of KGA were 
positively correlated with the MAP-2 levels (Figure 4.1D). Similarly, there were 
significant correlation between the mRNA levels of GAC and MAP-2 (Figure 
4.1E). 
In parallel to mRNA levels, the protein levels of MAP-2 continuously 
increased throughout the period of neuronal differentiation, confirming 
successful ongoing neuronal differentiation of the cultured cells (Figure 4.2A-B). 
Likewise, both KGA and GAC were upregulated during neuronal differentiation 
(Figure 4.2A, C-D). KGA protein had 3-fold and 4.5-fold upregulation at 7 days 
and 13 days after differentiation, respectively (Figure 4.2C). Similarly, GAC 
protein had 2-fold and 3.5-fold upregulation at 4 days and 7 days after 
differentiation, respectively (Figure 4.2D). The protein levels of KGA were 
positively correlated with the MAP-2 levels (Figure 4.2E). Similarly, there were 
significant positive correlation between the protein levels of GAC and MAP-2 
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(Figure 4.2F). Together, the upregulation of KGA and GAC and their correlation 
with MAP-2 during neuronal differentiation suggests that KGA and GAC may be 
required for NPC to differentiate into neurons.  
siRNA silencing of GLS1 impairs neuronal differentiation 
To test whether KGA and GAC were required for neuronal differentiation, 
we used siRNA to specifically silence GLS1 expression in NPC. The GLS1 
siRNA-transfected NPCs were induced to differentiate in neuronal media for 6 
days. The knockdown of GLS1 was confirmed firstly through Real-time PCR, 
which demonstrated significant decreases of the mRNA levels of both KGA 
(Figure 4.3A) and GAC (Figure 4.3B) compared with the control siRNA group. 
The knockdown was further confirmed by Western blot as the protein levels of 
both KGA (Figure 4.4A-B) and GAC (Figure 4.4A, C) were significantly 
decreased in siGLS1 group. In addition, the glutamate levels were also found 
reduced in siGLS1 groups (Figure 4.4D). After siRNA knockdown of GLS1, 
MAP-2 mRNA and protein levels were reduced to greater than 50% of that in 
control siRNA-transfected cells (Figure 4.3C, Figure 4.4E). The reduction of the 
mature neuronal marker MAP-2 in GLS1-deficient cells indicates that GLS1 is 
required for neuronal differentiation.   
To further characterize the morphological changes of neurons transfected 
by GLS1 siRNA, we labeled MAP-2 in the differentiated cultures through 
immunocytochemistry (Figure 4.5A). Human NPCs transfected with random 
control siRNA had approximately 70% of the cells positive for MAP-2 (Figure 
4.5B) at 6 days after differentiation. However, NPCs transfected with siRNA 
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targeting GLS1 had significantly lower percentage (40%) of cells positive for 
MAP-2 (Figure 4.5B). The impairment was specific to neuronal differentiation 
because the astrocytes differentiation, as determined by GFAP immunostaining, 
did not appear to alter after GLS1 knockdown when compared with control 
siRNA group (Figure 4.5C). These data suggest that GLS1 is required for the 
formation of mature neurons. 
siRNA silencing of GLS1 impairs NPC proliferation 
NPC proliferation is also a key step of neurogenesis. To determine 
whether deficiency of GLS1 affected NPC proliferation, we transfected NPCs 
with siRNA targeting GLS1 and kept the culture in NPIM for 3 days. The 
decreases of KGA and GAC mRNA levels by GLS1 siRNA transfection in NPCs 
were confirmed by Real-time RT-PCR (Figure. 4.6A-B). Via 
immunocytochemistry that labeled the Ki67+ cells, we were able to determine the 
levels of NPC proliferation in the culture. The percentage of Ki67-positive cells 
was significantly decreased when GLS1 was knocked down (Figure 4.6C-D). 
This suggests a critical role of GLS1 in the NPC pool expansion.  
siRNA silencing of GLS1 impairs NPC survival 
Next, we determined NPC survival after GLS1 was knocked down by 
siRNA. The levels of apoptosis were identified by Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) assay. DNA fragmentation was 
detected by TUNEL through the labeling of the terminal end of nucleic acids. We 
applied TUNEL assay to undifferentiated NPCs kept in NPIM. siGLS1 
significantly increased the percentage of TUNEL positive cells in the human 
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NPC culture, compared with siRNA control group (Figure 4.7A-B). Therefore, 
the TUNEL assay identified the existence of more cellular apoptosis when GLS1 
was deficient. To further confirm the apoptosis, we examined poly ADP ribose 
polymerase (PARP) cleavage in the NPCs that are GLS1-deficient. PARP is 
deactivated and cleaved by activated caspase 3 (cleaved caspase 3) in the 
apoptosis cascade, thus cleaved PARP represents ongoing apoptosis. Western 
blot analysis revealed the presence of cleaved PARP in both control and GLS1 
siRNA groups. However, Cleaved PARP was apparently at higher levels in 
GSL1 siRNA group compared with control siRNA group (Figure 4.7C-D). These 
data demonstrate the occurrence of cellular apoptosis after GLS1 was knocked 
down. 
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4.5 Discussion 
Neurogenesis is a finely tuned and highly orchestrated process that 
includes maintaining and expansing the pool of neural stem/progenitor cells 
(NPC), migration of NPC, differentiation of NPC to neurons, neuronal survival 
and integration of newly-born neurons to the existing synaptic networks [145]. 
As a result, hindered or impaired neurogenesis often causes malformations of 
brain, disruptions of neural signal transduction, difficulties and deterioration of 
cognitive functions, as reviewed by Jessel and Sanes [141] [145-147]. Given the 
fundamental importance of neurogenesis to human health and diseases, factors 
involved in this process remain to be further illustrated. In the present study of 
this chapter, we show that GLS1 isoforms were upregulated and correlated with 
MAP-2 during neuronal differentiation (Figures 4.1-4.2). siRNA silencing of 
GLS1 in NPCs impaired their subsequent neuronal differentiation, suggesting 
GLS1 is critical for neuronal differentiation (Figures 4.3-4.5). Furthermore, we 
show reduced proliferation and increased apoptosis in GLS1-deficient cells, 
suggesting that GLS1 is required for NPC proliferation and survival (Figures 4.6-
4.7). Collectively, we characterized GLS1 regulation in NPCs and identified 
GLS1 as a one of the essential factors for neurogenesis. Therefore, globally 
knocking down GLS1 is not applicable. The initial hypothesis that by knocking 
down GLS1 in brain will we be able to reduce brain inflammation and 
neurotoxicity relating to HAND needs even more detailed and comprehensive  
examinations. 
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  GLS1 is an important mitochondrial enzyme for cell metabolism. Its 
expression increases during mammalian neural development and remains high 
in postnatal CNS, implying an essential role of GLS1 for neurogenesis. We 
report for the first time that deficiency of GLS1 leads to hindered NPC 
differentiation, impaired proliferation and undermined survival. This finding cross 
confirms the function of glutaminase on neurogenesis with the report that GLS2 
contributes to neuronal differentiation [163]. Due to the fact that GLS1 is the 
dominant glutaminase isoform expressed in mammalian CNS compared with 
GLS2, tight-regulation of GLS1 is of critical importance to brain development. 
            The identification of GLS1’s involvement in neurogenesis has an 
important clinical implication. GLS1, especially the GAC variant, has been 
revealed to regulate oncogenic transformation [164-166] or the progressions of 
excitotoxicity in HIV-1-associated neurocognitive disorders [84]. Therefore, 
inhibiting GLS1 may serve for therapeutic purpose in cancer treatment or 
neurodegenerative diseases. Indeed, inhibition of GLS1 by either a potent small-
molecule pharmacological  inhibitor or by siRNA knockdown slowed the growth 
of glioma cells [166], or prevented the oncogenic transformation of human 
breast cancer cells and B lymphoma cells [165]. Lack of one copy of Gls1 has 
blunted the tumorigenesis in an immune-competent mouse model of 
hepatocellular carcinoma [167]. Also, knocking down GAC in HIV-infected 
microglia or macrophages alleviated the damage to neurons co-cultured [84]. 
However, although knocking down GLS1 by siRNA apparently provides benefits 
in cancer or neurodegerative diseases’ therapies, our studies with NPC suggest 
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that it may have unintended consequences on neurogenesis and brain 
development as the properties and functions of NPCs were altered or impaired 
when GLS1 was deficient. Therefore, directing the GLS1 inhibitors or siRNA to 
the right area and specific cell type, and applying the inhibitors with right dose is 
of critical importance and requires further investigation. Moreover, Gls1 KO mice 
were lethal at postnatal day 1 due to glutamatergic synaptic transmission 
disruptions [168], and Gls1+/- mice exhibited reduced hippocampal activity and 
developed schizophrenia-like symptoms [169]. These studies on GLS1 knockout  
(Gls1 KO) mice are in agreement with our evaluation of the critical role of GLS1 
on neurogenesis, particularly on the formation of neuronal maturation and neural 
connections.  
         Neuronal differentiation, NPC proliferation, and NPC survival, are three 
components of neurogenesis examined in the study of this chapter. How GLS1 
functions to affect each of those components is currently unclear. However, 
there are some potential underlying pathways that GLS1 may take to assert its 
influential role. First, the product of GLS1-mediated deamination of glutamine, 
glutamate, is known to regulate neurogenesis. Interestingly, glutamate has been 
shown to possess dichotomous effects on neurogenesis, depending on its 
concentrations. Low-to-moderate concentrations of exogenous glutamate (10 
µM) introduced to cell or brain slice culture led to increased NPC proliferation 
and neurogenic potentials [156-158], whereas high concentrations of exogenous 
glutamate (300 µM) introduction to culture resulted in impeded DNA synthesis 
and reduced cellular proliferation [170]. Second, excess glutamate has a direct 
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toxic effect on mature neurons [171-174]. Excess glutamate produced by 
immune-ativated macrophages and microglia has been documented in several 
neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s 
disease, stroke, and HIV-associated neurocognitive dementia [84, 90]. Third, 
glutamate can serve as an alternative energy substrate for the TCA cycle. 
Therefore, GLS1 deficiency might have led NPC into a starvation-like state 
under which the normal activities like cellular proliferation and differentiation are 
weakened. In addition, cells lacking energy are known to switch to the apoptosis 
signaling cascade. It is likely that more than one pathway cross talks and plays 
out in the NPCs that are deficient of GLS1. More studies on glutamate signaling 
pathways leading to the impairment of NPC functions are needed.   
        In summary, our study demonstrated that GLS1 is essential for 
neurogenesis in vitro. These data suggest that globally knocking down GLS1 is 
not application and great caution should be taken when targeting GLS1 in 
cancer or neurogenerative disease therapy.  
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4.6 Figures 
 
Figure 4.1 Transcript levels of GLS1 isoforms, KGA and GAC, were 
upregulated during NPC differentiation to neurons. (A-C) Human NPCs 
were exposed to neuron differentiation medium for differentiation. At 0, 4, 7, and 
13 days after differentiation, mRNA was collected and expressions of MAP-2 
(A), KGA (B), and GAC (C) were analyzed using Real-time RT-PCR. Data were 
normalized to GAPDH and presented as fold change compared to NPC. Data 
are shown as the means ± SEM of three independent experiments with three 
different donors. (D-E) Correlation of the gene mRNA levels of KGA (D) and 
GAC (E) with MAP-2 was determined by Spearman correlation. * denotes P < 
0.05, *** denotes P < 0.001  compared with NPC, N = 3.  
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Figure 4.2 Protein levels of GLS1 isoforms, KGA and GAC, were 
upregulated during NPC differentiation to neurons. (A-D) Human NPCs 
were exposed to neuron differentiation medium for differentiation. At 0, 4, 7, and 
13 days after differentiation, protein was extracted and expressions of MAP-2 
(A-B), KGA (D), and GAC (D) were analyzed using Western blot. Data were 
normalized to beta-actin and presented as fold change compared to NPC. Data 
are shown as the means ± SEM of three independent experiments with three 
different donors. (E-F) Correlation of the protein levels of KGA (E) and GAC (F) 
with MAP-2 was determined by Spearman correlation. * denotes P < 0.05, *** 
denotes P < 0.001  compared with NPC, N = 3.  
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Figure 4.3 Lack of GLS1 impaired the expression of MAP-2 mRNA 
during neuronal differentiation. (A-C) Human NPCs were transfected by 
control siRNA or GLS1 siRNA and then exposed to neuron differentiation 
medium for 4 days and 6 days. mRNA was collected and the expressions of 
KGA at 4 days and 6 days (A), GAC at 4 days and 6 days (B), and MAP-2 at 4 
days and 6 days (C) were analyzed using Real-time RT-PCR. Data were 
normalized to GAPDH and presented as fold changes. Data are shown as the 
means ± SEM of three different donors. * P < 0.05,  ** P < 0.01, *** P < 0.001, 
compared with control siRNA group, N = 3. 
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Figure 4.4 Lack of GLS1 impaired the expression of MAP-2 protein 
during neuronal differentiation. (A-E) Human NPCs were transfected by 
control siRNA or GLS1 siRNA and then exposed to neuron differentiation 
medium for 4 days and 6 days. Total protein was collected and the expressions 
of KGA at 4 days and 6 days (A-B), GAC at 4 days and 6 days (A, C), and MAP-
2 at 4 days and 6 days (A, D) were analyzed using Western blot. Data were 
normalized to beta-actin and presented as fold changes. Intracellular glutamate 
levels were tested using the Amplex Red Glutamic acid / Gutamate oxidase 
Assay Kit (E).  Data are shown as the means ± SEM of three different donors. * 
P < 0.05,  ** P < 0.01, *** P < 0.001, compared with control siRNA group, N = 3. 
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Figure 4.5 Lack of GLS1 impaired neuronal differentiation. Human 
NPCs were transfected by control siRNA or GLS1 siRNA and then exposed to 
neuron differentiation medium for 6 days. The cultured cells were fixed and 
stained with MAP-2 to determine the levels of neuronal differentiation. (A) 
Representative pictures of MAP-2+ (green) and GFAP+ (red) were shown. Nuclei 
were labeled with DAPI (blue). (B-C) The percentages of MAP-2+ cells (B) and 
GFAP+ cells (C) were determined by counting the number of MAP-2+ or GFAP+ 
cells over the number of DAPI+ cells in each microscopic field. Images were 
acquired from a Zeiss META 510 confocal microscope. Magnifications: 20X 
objective lens. Scale bar = 50 µm. Data are shown as means ± SEM of 10 fields 
in each experimental group for the three donors. *** P < 0.001, compared with 
control siRNA group, N = 3.  
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Figure 4.6 GLS1 silencing reduced NPC proliferation. Human NPCs 
were transfected by control siRNA or GLS1 siRNA, then kept in NPIM for 3 
days. NPC proliferation was determined by immuno-labeling the Ki67 of 
proliferating cells in each culture. (A-B) KGA and GAC mRNA levels were 
confirmed to be reduced in NPCs transfected by siGLS1 kept in NPIM. (C) 
Representative pictures of Ki67+ (green) cells in control siRNA- and siGLS1-
transfected NPC cultures were shown. Nestin (red) was used to label NPCs. 
Nuclei (blue) were labeled with DAPI. (D) The percentage of Ki67+ cells was 
determined by counting the number of Ki67+ cells over the number of DAPI+ 
cells in each microscope field. Images were acquired from a Nikon Eclipse 
TE2000E fluorescent microscope. Magnifications: 20X objective lens. Scale bar 
= 50 µm. Data are shown as means ± SEM of 10 fields in each experimental 
group for the three donors. * P < 0.05,  ** P < 0.01, *** P < 0.001, compared with 
control siRNA group, N = 3. 
  
  98 
 
  99 
 
Figure 4.7 GLS1 silencing increased NPC apoptosis. Human NPCs 
were transfected by control siRNA or GLS1 siRNA, then kept in growth media 
for 3 days. NPC apoptosis was determined by TUNEL assay and PARP 
cleavage. (A) Representative pictures of TUNEL+ (green) cells in control siRNA- 
and siGLS1-transfected NPC cultures were shown. Nestin (red) was used to 
label NPCs. Nuclei (blue) were labeled with DAPI. (B) The percentage of 
TUNEL+ cells was determined by counting the number of TUNEL+ cells over the 
number of DAPI+ cells in each microscope field. (C) Whole cell lysates were 
collected and NPC apoptosis was analyzed by Western blot for PARP cleavage. 
Beta-actin was used as loading control. (D) PARP cleavage levels were 
normalized as a ratio of cleaved PARP to actin after densitometric quantification 
of panel C and shown as fold change relative to control siRNA group. Images 
were acquired from a Nikon Eclipse TE2000E fluorescent microscope. 
Magnifications: 20X objective lens. Scale bar = 50 µm. Data are shown as 
means ± SEM of 10 fields in each experimental group for the three donors. * P < 
0.05, compared with control siRNA group, N = 3.  
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5.1 Summary and General Discussion 
Cognitive impairment in HAND is a consequence of synaptic network 
damage in basal ganglia, cerebral cortex and hippocampus of HAND patients. 
Chronic neuroinflammation is a hallmark of HAND and a constitutive component 
of the pathogenesis of various neurodegenerative diseases including HAND. 
HIV-infected and immune-activated microglia and macrophages instigate brain 
inflammation and induce neuronal injury [27, 175, 176] through the production 
and release of various soluble neurotoxic factors including glutamate [30, 32, 
37, 40-52]. Excess glutamate has the potential to induce extensive neuronal 
injury. Apart from microglial and macrophages, neurons play a critical role in the 
progression of brain inflammation as well. Proinflammatory cytokines TNF-α and 
IL-1β, which are typically elevated during neurodegenerative diseases, induced 
neuronal loss via the production and release of excess glutamate from neurons 
treated by the inflammatory cytokines [53]. Therefore, apart from the 
macrophage- and microglial-neuronal interaction, the neuronal-neuronal 
interaction has a major pathogenic role in the progressions of excitotoxicity and 
neuroinflammation through excess glutamate.  
Our central objective focuses on the in vivo investigations of the primary 
glutamate-producing enzyme in CNS, GLS1, in the neuropathogenesis of 
HAND. Our laboratory has documented the abberant upregulation of GLS1 as a 
key pathogenic event in excess glutamate production and augmentation of brain 
inflammation and neurotoxicity in macrophages, microglia, and inflammatory 
neurons in vitro [50, 86, 90] [53]. This suggests that GLS1 may be a novel 
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therapeutic target for treating HAND. In order to further determine the 
pathogenic role of dysregulated GLS1, we have utilized integral animal models.  
Our endeavor towads the central objective started with investigations of 
the regulation of GLS1 in the CNS of HAND murine models. Based on the 
revelation of elevated glutamate in the plasma and CSF of HIV-1-infected 
individuals, and the finding of the isoform-specific upregulation of GAC in 
postmortem brain tissues of HAND patients from previous studies, we 
hypothesize that there is strong association between GLS1 dysregulation with 
brain inflammation and cognitive impairment of HAND animals. In chapter 2, we 
show indeed that the GLS1 isoforms KGA and GAC were upregulated in the 
whole brain tissues of HIV-Tat Tg mouse and in the neuroinflammatory areas of 
HIVE-SCID mouse brains. Both HIV-Tat Tg mouse and HIVE-SCID mouse 
exhibited impairment in spatial learning and memory as revealed by MWM test. 
Importantly, the elevated GLS1 expression levels were significantly correlated 
with the increased CNS reactive astrogliosis and impaired spatial learning and 
memory of HIV-Tat Tg mouse. These data support our central hypothesis that 
there is strong association between GLS1 dysregulation with CNS inflammation 
and cognitive impariment of HAND mouse, suggesting that GLS1 dysregulation 
might contribute to HAND pathogenesis via mediating brain inflammation and 
excitotoxicity.  
But whether there is a causal-effect relationship between GLS1 
dysregulation and CNS disorder in HAND remains unclear. Therefore, we next 
investigate whether the brain-specific overexpression of GLS1 will have a causal 
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effect on neurotoxicity and synaptic damage leading to cognitive deteriorations 
in relevance to HAND pathogenesis. In chapter 3, we have generated the 
Nestin-GAC mouse which has the overexpression of GAC specific to brain. By 
characterizing the pathology and behaviors of Nestin-GAC mouse, we report 
that the brain-specific overexpression of GAC leads to hippocampal and cortical 
synaptic network damage, increased apoptosis and reactive astrogliosis in the 
hippocampi and cortices of mice. Importantly, we have found impairment of LTP 
in Nestin-GAC mice, further demonstrating the synaptic damage in hippocampi 
of these animals. Together, these results indicate for the first time that the 
overexpressed GAC in brain has a causal-effect relationship with prolonged 
brain inflammation and increased apoptosis, leading to neural network damage 
and finally resulting in the impairment of cognitive functions of animals. Many of 
these pathological changes including reactive astrogliosis, neuronal injury, and 
cognitive impairment of learning and memory are in parallel to those seen in 
HIV-Tat Tg mouse.  
There are two major issues of the CNS pathological profiles of Nestin-
GAC mouse remainning to be addressed. First, the regulation of glutamate 
receptors in Nestin-GAC mouse brains is an interesting and important question 
to be answered. Excitotoxicity is a commonplace in various neurodegenerative 
diseases  including HAND. Overactivation of NMDA receptors is a major 
component of excitotoxicity. High-affinity NMDA receptor antagonist MK801 has 
blocked the toxicity from neurons treated by inflammatory cytokines TNF-α and 
IL-1β [53]. And more importantly, a low-to-moderate-affinity NMDA receptor 
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antagonist memantine has substantially abrogated neurotoxicity and largely 
mitigated the impairment of  synaptic transmission and LTP [111]. Determining 
whether or not the neurotoxicity observed in Nestin-GAC mouse brains is via the 
overactivation of NMDA receptors will greatly facilitate our endeavor to further 
validate the resemblance of Nestin-GAC mouse as a novel HAND murine 
model.  
Apart from the alterations of glutamate receptors, to study whether there 
are dysregulations or dysfunctions of glutamate transporters in Nestin-GAC 
mouse is of equal importance. Glutamate transporters are crucial for glutamate 
uptake and regulating glutamate homeostasis [135]. Therefore, they are 
important for buffering against excess glutamate-mediated excitotoxicity in the 
brain. Previous studies have revealed that deregulation or loss of function of 
glutamate transporters EAAT1 and EAAT2 on astrocytes are involved in neural 
inflammation and neurotoxicity [91, 136, 137]. EAAT2 expression levels were 
largely reduced on inflammatory cytokines-treated astrocytes via the 
upregulation of EAAT2 repressors by astrocyte-elevated gene 1 (AEG-1) [91]. 
Importantly, by enhancing EAAT1 activity the investigators are able to diminish 
neural damage and recover cognitive impairment [138, 139]. Therefore, we 
speculate that there can be dysregulations or loss-of-function of certain 
important glutamate transporters in Nestin-GAC mouse brain and the 
dysfunction of glutamate transporters exaggerate neuroinflammation and 
neuronal injury.  
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At current stage, we have determined the aberrant upregulation of GLS1 
isoforms KGA and GAC in the whole brain tissues of HIV-Tat Tg mice, and we 
have found causality between GLS1 dysreulgation and neurotoxicity. One 
important question to be answered next is to document the expression profiles 
of KGA and GAC in different areas of HIV-Tat Tg mice brains. Unlike HIVE-
SCID mice which have the HIV-1-infected MDM injected into the basil ganglia 
thus displaying most of the neuroinflammatory and neurotoxic responses there, 
HIV-Tat Tg mice carry the expression of Tat almost globally in CNS [96, 97]. 
Therefore, the spatial profile of GLS1 dysregulation in HIV-Tat Tg mouse CNS is 
expected to be discrepant from that in HIVE-SCID mouse CNS. Our previous 
data revealed that the majority of GLS1 aberrant upregulation in HIVE-SCID 
mouse CNS was found in neurons of the inflammatory area [53]. Studies on the 
brain areas that display most extensive and severe neural injury revealed that 
the neuronal damage is largely localized in the cerebellum and cortex of HIV-Tat 
Tg mouse [101]. Besides, relatively subtle neural damages including reductions 
in spine density and malformations of dendrites of neurons were found in the 
whole brain of HIV-Tat Tg mouse [106]. In consideration of developing GLS1 
inhibitors for therapeutic purpose, it is important to locate the specific cell type 
and possibly the specific brain area that has the majority of GLS1 dysregulation 
in HIV-Tat Tg mouse.  
Besides the spatial profile of GLS1 dysregulation, to know the temporal 
regulation profile of GLS1 in HIV-Tat Tg mouse is equally important. This will 
help to determine the sequence of inflammatory and neurotoxic events occuring 
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in HIV-Tat Tg mouse brain. It is interesting to dissect the effect of GLS1 
dysregulation on brain excitotoxcity during different life stage. To achieve this, a 
tamoxifen-controlled temporal Tg mouse model is of great help. 
Taken together, these results so far demonstrate the pathogenic role of 
the aberrantly-overexpressed brain GLS1 in vivo and suggest that dysregulated 
GLS1 under pathological conditions can be a novel therapeutic target for 
slowing or reversing HAND progressions and diminishing HAND-related 
complications. Because of that, to develop glutaminase inhibitors that target 
specific isoform of the enzyme and target specific cell types are one of the 
promising approaches for next step. Likewise, genetic approaches aiming to 
knock down the expression levels of glutaminase in specific types of cells have 
also been proposed as a promising therapeutic approach. However, great 
caution should be taken when targeting GLS1 in HAND therapy by genetical 
methods as we have identified an essential role of GLS1 in NPC functions. In 
chapter 4, we show that GLS1 isoforms were upregulated and correlated with 
MAP-2 during neuronal differentiation. siRNA silencing of GLS1 in NPCs 
impaired their subsequent neuronal differentiation. And we report reduced 
proliferation and increased apoptosis in GLS1-deficient cells. These results 
suggest that GLS1 is essential for the differentiation, proliferation and survival of 
NPC. Therefore, knocking down GLS1 globally in the brain is not applicable for 
therapeutic purpose. We will need to develop conditional knockout (cKO) mouse 
model with the expression of GLS1 temporally controlled in specific cell types. 
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5.2 Future directions 
First, a lack of GLS1 cKO murine model has hindered further 
investigations of GLS1 functions in disease and in adult CNS due to early 
lethality of GLS1 KO mouse on the first day after birth. To establish GLS1 as a 
therapeutic target in HAND and further elucidate the underlying mechanisms, 
we will generate GLS1 cKO mouse with tamoxifen-inducible temporal control 
and GLS1 specifically deleted in macrophages and microglia by crossing the 
GLS1-floxed mice with Csf1R-CreER mice. The resulting Csf1R-GLS1-/- mouse 
will have GLS1 knocked out only in macrophages and microglia with the 
temporal control of tamoxifen. To investigate whether the deletion of GLS1 in 
macrophages and microglia can diminish or reverse the destructive effects of 
HIV-Tat expression in mouse brain, we will cross the Csf1R-GLS1-/- mouse with 
HIV-Tat Tg mouse. Behavioral assessment will be performed and subsequent 
pathological and electrophysiological characterizations will be done. 
Second, we will evaluate the neuroprotective effect of GLS1 inhibitors in 
the HIV-Tat Tg mouse and GLS1-overexpression Tg mouse. Immediately after 
the induction of Tat or the GLS1 overexpression, GLS1 inhibitors will be 
continuously administered via intraperitoneal injection daily. Behavioral 
evaluations will be performed. Subsequently, brain tissues of HIV-Tat Tg mice or 
GLS1-overexpression Tg mice will be collected for pathological or physiological 
characterizations.  
Third, we will carry out the genomic and proteomic analyses of 
regulations on glutamate transporters and the subunits of glutamate receptors in 
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our GLS1-overexpression Tg mouse and compare with that in HIV-Tat Tg 
mouse. Although NMDA receptors are known to be the major player in 
excitotoxicity and the resultant neurological disorders, alterations in glutamate 
transporters and other glutamate receptors also clearly have a role in it [91, 136, 
137] [138, 139]. This will be of great help to expand the regulation profiles of key 
molecules involved in HAND progressions and identify new potential therapeutic 
targets apart from GLS1 itself and NMDA receptors. And next to that, the effort 
will be put on the evaluations of the neuroprotective potential by normalizing 
these newly-defined dysregulated molecuels. 
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5.3 Figures 
Figure 5.1 Summary of the pathogenic role of GLS1 dysregulation in 
HAND. GLS1 isoforms KGA and GAC were upregulated in the whole brain 
tissues of HIV-Tat Tg mouse. HIV-Tat Tg mouse exhibited impairment in spatial 
learning and memory as revealed by MWM test. Importantly, the elevated GLS1 
expression levels were significantly correlated with the increased CNS reactive 
astrogliosis and impaired spatial learning and memory of HIV-Tat Tg mouse. 
Brain-specific overexpression of GAC leads to hippocampal and cortical 
synaptic network damage, increased apoptosis and reactive astrogliosis in the 
hippocampi and cortices of mice. We have found impairment of LTP in Nestin-
GAC mice, further demonstrating the synaptic damage in hippocampi of these 
animals.  
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